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ABSTRACT 
ROLE OF HUMAN ARYLAMINE N-ACETYL TRANSFERASE IN CARCINOGEN 
METABOLISM AND HUMAN BREAST CANCER PROGRESSION 
Carmine S. Leggett 
August 16, 2012 
Human arylamine N-acetyltransferase (NAT) is a phase II cytosolic 
enzyme that occurs as two isozymes, NAT1 and NAT2. This family of 
polymorphic enzymes catalyzes the detoxification and/or activation of many 
aromatic and heterocyclic amine drugs and carcinogens. These metabolism 
reactions can lead to detoxification of xenobiotics by N-acetylation, or 
bioactivation by O-acetylation which is preceded by cytochrome P450 (CYP) 
hydroxylation. This study evaluates the role of human arylamine N-
acetyltransferase in carcinogen metabolism as it pertains to substrate selectivity, 
kinetic activity towards arylamine and alkylaniline substrates, and toxicological 
risk. Here we introduce the use of immortalized human fibroblasts (GM4429) to 
investigate the effects of combinations of human NAT1, human NAT2 haplotypes 
(NA T2*4, NA T2*S8, or NAT2*78), and varying CYP1 A2 enzymatic activity on 
carcinogen metabolism. We determined the apparent Michaelis-Menten 
constants of human NAT1 and human NAT2 for several well-characterized and 
vi 
putative environmental carcinogens. We utilized these data to investigate NAT 
substrate selectivity for these compounds of interest. 
NAT1 has been implicated in several cancers including urinary bladder, 
colorectal, lung, and breast cancer. Studies suggest that NAT1 plays an 
important role in cell growth and survival, as well as in cell proliferation and cell 
invasion, which are hallmarks of metastatic cancer. Here we describe the use of 
computational screening to identify effective, novel small molecule inhibitors of 
the molecular target NAT1. Our lead compound, Compound 10, suppressed 
carcinogen metabolism and 4-aminobiphenyl (ASP) -induced DNA adducts. The 
results in this study show that upon NAT1 inhibition there is a significant 
decrease in ASP activation, cell invasion, and cell proliferation in human breast 
adenocarcinoma cells. We also show that NAT1 inhibition in human breast 
cancer cells resulted in mitotic arrest, which supports findings suggesting that 
NAT1 plays an important role in human breast cancer progression. Our results 
indicate that human NAT1 is a molecular target for cancer therapy. 
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CHAPTER I 
BACKGROUND AND SIGNIFICANCE 
Arylamine N-Acetyltransferase Function and Characterization 
Human arylamine N-acetyltransferase (NAT) is a phase II xenobiotic 
metabolizing enzyme that catalyzes the N- and 0- acetylation of many arylamine 
drugs and environmental carcinogens (Figure 1.1). NAT catalyzes the N-
acetylation of substrates by transferring an acetyl group from acetyl coenzyme A 
to the exocyclic nitrogen of aromatic or heterocyclic amines. This step is 
described as the detoxification pathway because these innocuous N-acetylated 
substrates are excreted from the body. If compounds are first N-hydroxylated by 
cytochrome P450 (CYP) enzymes, the N-hydroxlated substrates can then be 
further activated by NAT-catalyzed O-acetylation. This bioactivation reaction 
leads to the formation of N-acetoxy substrates. These very unstable N-acetoxy 
metabolites spontaneously form highly reactive electrophilic arylnitrenium ions 
that can react with DNA produCing DNA adducts that can lead to mutagenesis 
and initiate cancer. 
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Figure 1.1 Metabolism reactions catalyzed by arylamine N-
acetyltransferase. Adapted from Bendaly et aI., 2007. 
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Arylamine N-acetyltransferase occurs in two human isozymes, NAT1 and 
NAT2, that share 87% nucleotide homology. Despite their high homology, they 
differ in substrate specificity and tissue distribution (Hein, 2002). Human NAT1 
has a widespread distribution in adult tissues including the liver, while human 
NAT2 is expressed mainly in the liver and intestine (Russell et aI., 2009). Both 
isozymes possess a functional Cys-His-Asp catalytic triad that allows the transfer 
of an acetyl group for acetyl coenzyme A in a ping-pong bi-bi reaction 
mechanism (Hein, 2009). Site-directed mutagenesis of individual amino acids 
demonstrated that substrate selectivity is strongly influenced by three key active 
site loop residues F125, Y127, and R129 (Goodfellow et aI., 2010). For example, 
NAT1 selectively acetylates p-aminobenzoic acid (PABA) and p-aminosalicyclic 
acid (PAS), whereas NAT2 preferentially acetylates sulphamethazine (SMZ) and 
procainamide. 
p-Aminobenzoylglutamate (PABG), a folic acid catabolite, is the only 
known endogenous substrate for NAT. PABG is N-acetylated by NAT1 
suggesting an endogenous role for NAT in folate metabolism and embryonic 
development (Minchin, 1995). NAT1 polymorphisms have been associated with 
incidences of spina bifida and limb deficiency defects further suggesting that 
there is a critical endogenous role for N-acetyltransferases (Minchin, 1995). The 
endogenous role of NAT is not fully understood. Studies are needed investigated 
to determine the role that NAT plays in development and carcinogen metabolism. 
3 
NH 2 
Figure 1.2 Chemical structures of selected N-acetyltransferase substrates. 
Arylamine environmental carcinogens 4-aminobiphenyl, 2-aminofluorene, 
benzidine and alkyanilines 2,5-dimethylaniline, 2,6-dimethylaniline, 3,4-
dimethylaniline, 3,5-dimethylaniline, and 3-ethylaniline. (from left to right). 
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As seen in Figure 1.2, N-acetyltransferase metabolizes a number of 
aromatic and heterocyclic amine carcinogens. Some examples include 
environmental carcinogens found in cigarette smoke and meats cooked at high 
temperatures, such as 4-aminobiphenyl (ABP), 2-aminofluorene (AF), and 2-
amino-1-methyl-6-phenylimidazo [4,5-b]pridine (PhIP) (Walker et aL, 2009). 
Exposure to ABP, which is present in tobacco smoke (2.4 - 4.6 ng per 
cigarette), has been associated with bladder cancer risk (Liu et aL, 2007). AF, 
whose N-acetylated derivative was developed as an insecticide, is associated 
with mutagenesis (Sugamori et aL, 2003). Although some arylamine substrates 
such as ABP and AF are metabolized by both NAT1 and NAT2, each NAT 
isozyme exhibits substrate specificity (Liu et aL, 2007). Capacities of human 
NAT1 to catalyze the metabolic activation of N-hydroxy-2-acetylaminofluorene 
and N-hydroxy-4-acetylaminobiphenyl via N,O-acetylation were lower than the 
metabolic rates of N-hydroxy-2-aminofluorene and N-hydroxy-4-aminobiphenyl 
via O-acetylation (Hein et aL, 1993). ABP and AF both produce dG-C8-adducts, 
but the mutation pattern for each compound is different. dG-C8-AF produces 
both frameshift and base-substitution (G to T) mutations, and dG-C8-ABP 
produces only base-substitution (G to A) mutations (Beland et aL, 1983). 
Other compounds metabolized by NAT enzymes include alkylaniline 
(monocyclic arylamines) genotoxicants 2,5-dimethylaniline (2,5-DMA),- 2,6-
dimethylaniline (2,6-DMA), 3,4-dimethylaniline (3,4-DMA), 3,5-dimethylaniline 
(3,5-DMA), and 3-ethylaniline (3-EA). Arylamine genotoxicants 2,6-DMA and 
3,5-DMA are present in cigarette smoke and pollution from industrial sources. 
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The alkylanilines 2,6-DMA , 3,5-DMA, and 3-EA are associated with bladder 
cancer among the general population including non-smokers (Liu et aL, 2007). 
Exposure to these alkylanilines (monocyclic arylamines) is of particular interest to 
toxicological risk studies because of the wide distribution of these compounds in 
the environment resulting in ubiquitous exposure (Skipper et aL, 2010). Since 
these compounds are present in cigarette smoke, indoor spaces contaminated 
with cigarette smoke exhibit higher levels of alkylanilines than in uncontaminated 
spaces. Industrial sources also provide significant levels of exposure to these 
compounds (Skipper et aL, 2010). 
It is important to note that in previous studies conducted in Italy, 2,6-DMA 
levels were higher among non-smokers than smokers illustrating the 
environmental significance of monocyclic arylamine exposure is extensive and is 
not confined to groups such as active smokers or those subjected to 
occupational exposure (Skipper et aL, 2010). This suggests that environmental 
exposure is as important as active smoking exposure. The arylamine 
compounds explored in this study were chosen because they are general 
environmental pollutants that potentially have a detrimental impact on the total 
population due to the possibility of toxicological risk. 
Both NAT1 and NAT2 are capable of N-acetylating arylamines and 
alkylanilines to innocuous compounds that are less reactive and excreted. Since 
these isozymes are differentially expressed in tissues, substrate selectivity may 
have a profound effect on the detoxification or bioactivation of alkylanilines. 
NAT2 polymorphisms have been shown to play an important role in the 
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bioactivation and detoxification of arylamine and hydrazine drugs and 
carcinogens. While previous studies have sought to better understand the 
carcinogenicity and genotoxicity of these compounds, none have determined the 
effects of NAT2 genetic polymorphisms on the metabolism of alkylanilines. 
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Human Arylamine N-Acetyltransferase Genetic Variants 
and Functional Genomic Studies 
Human arylamine N-acetyltransferase polymorphisms were first identified 
when patients prescribed the anti-tuberculosis drug isoniazid experienced 
varying toxic side-effects. It was later discovered that N-acetyltransferase 
polymorph isms were responsible not only for the variations in metabolism of this 
hydrazine drug, but also of environmental carcinogens consequently altering risk 
posed by the activation of carcinogens. Polymorphisms in the NAT genes have 
been shown to affect the acetylator phenotype (Hein, 2006). 
Molecular epidemiological studies have reported associations between 
NAT polymorph isms and individual risk of several diseases including cancer. 
Functional genomic studies have been done in E. coli (Hein et aL, 1994), yeast 
(Fretland et aL, 2001), COS-1 cells (Zang et aL, 2007) and Chinese hamster 
ovary cells (Metry et aL, 2007) to better understand the relationship between 
haplotype and disease risk. These studies have provided valuable information 
adding to our understanding of the effects that genetic variations have on 
disease susceptibility and toxicological risk, but these relationships are not fully 
understood. 
The reference allele NA T2*4, which is associated with rapid acetylation, 
and over 32 NA T2 allelic variants have been identified in human populations 
(Walker et aL, 2009). These alleles contain nucleotide substitution sites 
throughout the NAT2 coding regions that cause functional consequences of 
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altered (rapid or slow) acetylator phenotype. Two alleles of interest associated 
with slow acetylator phenotype are NA T2*58 and NA T2*78. NA T2*58 
possesses three single nucleotide polymorphisms (SNPs) in the NAT2 open 
reading frame T341C (1114T), C481T (synonymous), and A803G (K268R), 
whereas NA T2*78 is associated with two SNPs in the NAT2 open reading frame 
C282T (synonymous) and G85?A (G286E) (8endaly et aI., 2009). Studies have 
shown that the T341 C SNP associated with the NAT2*58 allele causes a 
reduction in protein due to enhanced protein aggregation and/or targeting for 
degradation (Walraven et aI., 2008). It is postulated that this polymorphism 
reduces hydrophobic interactions at the interface between the domain II beta 
barrel and the domain I helix, altering protein folding resulting in protein 
degradation. The G85? A SNP associated with the NA T2*78 allele results in 
altered active site access and altered substrate affinity which causes substrate-
dependent activity changes. It is believed that this polymorphism alters the 
conformation of the C-terminal tail adjacent to the active site opening due to 
steric clashes with nearby residues. 
Although epidemiological studies suggest that genetic polymorph isms are 
associated with increased susceptibility to various cancers related to 
environmental carcinogen exposure, further experimental studies are needed to 
strengthen these findings. Previous studies in our laboratory investigated the 
effects of NAT2 genetic variants on 2-amino-1-methyl-6-
phenylimidazo[4,5b]pyridine (PhlP) induced DNA adduct formation and 
mutagenesis in nucleotide excision repair (NER)-deficient Chinese hamster ovary 
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(CHO) cells that recombinantly express human CYP1 A2 and human NAT2*4 or 
NAT2*58 alleles (Metry et aI., 2007). This study provides evidence in support of 
the ability to study mutagenesis and DNA damage in a cell line stably transfected 
with human NAT2 alleles and human CYP1 A2. 
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Arylamine N-Acetyltransferase 1 and Cancer 
NAT1 is found in almost all tissues of the body (Hein, 2009). NAT1 mRNA 
levels have been associated with several cancers including breast, urinary 
bladder, esophageal, and gastric cancers (Tiang et aL, 2010). Analysis of gene 
expression profiles of 39 breast cancers showed that NAT1 clustered with 
expression of the estrogen receptor (ER) (Walker et aL, 2009). Studies also 
revealed the higher expression of NAT1 in luminal carcinomas compared to 
basal-like carcinomas (Zheng et aL, 1999). These reports support the use of 
NAT1 as a biomarker and potential molecular target for cancers, especially 
breast cancer. 
Studies suggest that NAT1 plays an important role in cell growth and 
survival, as well as in cell proliferation and cell invasion, which are hallmarks of 
metastatic cancer (Tiang et aL, 2010). When NAT1 was over-expressed in an 
immortalized breast epithelial cell line, cells showed increased proliferative 
capacity and the ability to grow in low serum media (Adam et aL, 2003). In a 
RNAi-mediated knock-down study, Tiang et al. (2011) showed that NAT1 knock 
down in colon adenocarcinoma cells resulted in a marked increase in cell-cell 
contact growth inhibition, a loss of cell viability at confluence, and an up-
regulation of the cell adheSion molecule E-cadherin (Tiang et aL, 2011). The 
human NAT1 gene is overexpressed highly in ER+ breast cancer cells and in 
invasive ductal and lobular breast carcinomas (Adam et aL, 2003) suggesting 
that NAT1 is important to cancer progression and cancer cell biology, particularly 
breast cancer. There have been many molecular epidemiological studies 
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associating NAT1 polymorphisms and increased cancer risk. (Minchin et aI., 
2007). The close association between NAT1 polymorphisms and risk for cancer 
suggests a potential clinical benefit of NAT1 inhibition. For example, in 
comparison with all other NAT1 genotypes the rapid acetylator genotype 
(NAT1*10) was elevated in human bladder (Bell et aI., 1995) and breast (Zheng 
et aI., 1999) cancers. These data suggest that NAT1 plays an important role in 
cancer progression which supports the use of NAT1 as a molecular target for 
novel cancer therapeutics. 
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Specific Aims and Hypotheses 
This dissertation project encompasses two specific aims. Listed are the specific 
aims and the hypothesis behind each aim. The following chapters describe the 
experiments performed to test these hypotheses, the analyses of the results, and 
conclusions. 
Specific Aim I Hypothesis 
We hypothesize that xenobiotic-metabolizing enzyme phenotypes (Le., rapid or 
slow) and substrate selectivity will impact carcinogen metabolism. 
Specific Aim I 
To investigate the effects of combinations of human NAT1, human NAT2 
haplotypes (NAT2*4, NAT2*58, or NAT2*78), and varying CYP1A2 enzymatic 
activity on carcinogen metabolism in immortalized human fibroblasts. 
Specific Aim II Hypothesis 
We hypothesize that the inhibition of NAT1 enzymatic activity will reduce 
carcinogen activation and experimental cancer progression. 
Specific Aim II 
To identify novel small molecule inhibitors of human NAT1, and to evaluate the 
effects of inhibition of NAT1 on carcinogen metabolism and experimental cancer 
initiation and progression. 
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CHAPTER II 
FUNCTIONAL EFFECTS OF HUMAN NAT1, HUMAN NAT2 HAPLOTYPES 
(NAT2*4, NAT2*58, AND NAT2*78), AND HIGH AND LOW CYP1A2 
ENZYMATIC ACTIVITY ON CARCINOGEN METABOLISM 
INTRODUCTION 
Susceptibility to chronic diseases, such as cancer, involves interactions 
between genetic variations in the genes of xenobiotic metabolizing enzymes 
(XMEs) and the environment. The effects of genetic variance on toxicological 
risk are not fully understood and require further investigation. Environmental 
arylamine and heterocyclic amine carCinogens are metabolized by XMEs such as 
arylamine N-acetyltransferases (NATs). Two isozymes, NAT1 and NAT2, 
catalyze the detoxification of aromatic and heterocyclic amines by N-acetylation 
(Hein et aI., 2000). NAT1 and NAT2 also catalyze the bioactivation of aromatic 
and heterocyclic amines. This bioactivation occurs by O-acetylation which is 
preceded by cytochrome P450 hydroxylation (Hein, 2000). The resulting 
arylamine acetoxy products are capable of spontaneously forming electrophilic 
arylnitrenium ions that covalently bond to DNA and proteins. These 
environmental carcinogen-induced DNA adducts can lead to mutagenesis and 
initiate cancer. 
NA T1 and NA T2 are highly polymorphic genes. The polymorphisms result 
in differences in the rate at which drugs and carcinogens are metabolized. 
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Polymorphisms in the NAT genes were first discovered after differences in 
toxicity were seen in patients treated with the anti-tuberculosis drug isoniazid 
(Hein, 2000). The differences in side effects such as numbness and tingling in 
the fingers, as well as other progressive damage to the nervous system, were 
attributed to single nucleotide polymorphisms (SNPs) in the NAT gene. To date 
over 32 human NAT2 polymorph isms have been identified as rapid, intermediate, 
and slow acetylator phenotypes. These SNPs determine acetylator phenotype by 
modifying enzyme function and stability. The functional roles of this family of 
enzymes have been studied to better understand the association of these 
polymorphic alleles with cancer risk. 
Carcinogens 4-aminobiphenyl (ASP) and 2-aminofluorene (AF) are 
metabolized by both NAT isozymes, illustrating that both NAT1 and NAT2 play 
an important role in arylamine carcinogen metabolism (Grant et aI., 1990) 
Exposure to ASP, which is present in tobacco smoke, has been associated with 
bladder cancer risk (Liu et aI., 2008). AF, whose N-acetylated derivative was 
developed as an insecticide, is associated with mutagenesis (Sugamori et aI., 
2007). Although some arylamine substrates such as ASP and AF are 
metabolized by both NAT1 and NAT2, each of the isozymes exhibits substrate 
specificity (Liu et aI., 2007). 
In addition to substrate specificity, allelic variations in the NAT2-
locus also play an important role in acetylation capacity, metabolic activation, and 
cancer risk (Hein, 2000). Many studies suggest a relationship between NAT2 
slow acetylator phenotype and cancers such as urinary bladder, colorectal, 
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breast, and lung cancers (Zang et aI., 2007). The results of these studies were 
inconsistent due to several factors including misclassification of smoking or 
occupational status, a misinterpretation of genotype and phenotype, and limited 
statistical power (Walker et aI., 2009). Acetylator phenotype may increase 
vulnerability to arylamine induced toxicological outcomes. Functional genomic 
studies that incorporate effects of acetylator phenotype did not consider other 
limitations. These study confounders include substrate specificity, genetic 
variations, and the study of interactions of various XMEs. 
In this study, we undertook experiments to assess the intrinsic capacities 
and substrate specificities of human NAT1 and NAT2 to catalyze the N-
acetylation of several environmental arylamine and alkylaniline carcinogens. We 
utilized nucleotide excision repair (NER) - deficient immortalized human 
fibroblasts to examine the effects of combinations of human NAT1, 3 common 
human NAT2 haplotypes (NAT2*4, NAT2*S8, or NAT2*78), and high and low 
CYP1A2 enzymatic activity on carcinogen metabolism. These human fibroblasts 
endogenously express human NAT1, and therefore provide a model to better 
understand the role that human NAT1 and NAT2 play in carcinogen metabolism. 
This human cell model also enables us to study NAT1 and NAT1 intrinsic 
capacities and substrate specificities. 
This study investigates the functional effects of altered CYP1 A2 activity 
and NAT2 haplotypes on carcinogen metabolism, DNA adduct levels, and 
mutagenesis in NER-deficient Simian Virus 40 (SV40)-transformed human skin 
fibroblast line GM4429. GM4429 cells were derived from a Caucasian 
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Xeroderma Pigmentosum (XP) complementation group A (XPA) patient 
exhibiting a delayed onset of neurological disease. These cells are widely used 
as a model of NER deficiency due to mutation of XPA (States et aL, 1996). 
Simian Virus 40, an oncogenic DNA virus, induces malignant transformation and 
causes a loss of cell cycle checkpoint control (States et aL, 1996). The large T-
antigen of the SV40 virus accomplishes abrogation of the cell cycle checkpoint 
by sequestering p53 which stops both G1 and G2 checkpoints (States et aL, 
2002). 
This study determines the specificity constants of recombinant human 
NAT1 and NAT2 for seven arylamine carcinogens benzidine, ASP, AF, 2,5-DMA, 
3,4-DMA, 3,5-DMA, and 3-EA. Here we provide new insight into the metabolic 
detoxification of persistent environmental carcinogens by arylamine N-
acetyltransferase N-acetylation. 
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MATERIALS AND METHODS 
Cells and Culture Conditions 
A clone of SV40-transformed human skin fibroblasts (GM4429) was the 
kind gift of Dr. J. Christopher States. GM4429 cells express endogenous NAT1, 
and are nucleotide excision repair deficient (NIGMS Human Mutant Cell 
Repository, Coriell Institute, Camden, NJ). Cells were cultured in alpha 
modification of minimal essential media (Cambrex, Walkersville, MD) 
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 100 U/mL 
penicillin (Lonza), 100 U/mL streptomycin (Lonza), and 2 mM L-glutamine 
(Lonza) at 3rC in 5% CO2 • Culture media was supplemented with appropriate 
selective agents (hygromycin and geneticin) to maintain stable transfectants. 
Stable Transfection 
Stable transfections were carried out in GM4429 fibroblasts using the Flp-
In system (Invitrogen) as described previously in CHO cells by Metry et aI., 
(2007). These cells were transfected with the pFRTllacZeo plasmid resulting in a 
single integrated FRT site. Cells were split 24 h after transfection and treated 
with medium supplemented with Zeocin (200 ~g/mL) 48 h after transfection, for 
selection according to the manufacturer's protocol. Zeocin - resistant clones 
were picked with cloning cylinders. The cell lines with a single intergrated FRT 
site determined by real-time polymerase chain reaction (PCR) and Southern blot 
screening were selected for additional transfection. The piRES plasmid 
containing cDNAs of human CYP1A2 and NADPH-cytochrome P450 reductase 
18 
gene (Invitrogen), was transfected into the newly constructed GM4429-FRT cell 
line using Effectene Transfection Reagent kit (Qiagen). Geneticin-resistant 
clones were isolated using cloning cylinders. Human NAT2 alleles (NAT2*4, 
NAT2*58, or NAT2*78) were transfected using the pcDNA5/FRT plasmid and co-
transfected with pOG44 (Invitrogen), a Flp recombinase expression plasmid, into 
GM4429-FRT-CYP1A2 cells. Stably transfected cells were selected by geneticin 
and hygromycin resistance. 
NA T mRNA expression (Tagman Quantitative RT-PCR Assays) 
TaqMan assays were used to assess levels of NAT1 and NAT2 mRNA 
expressed in each cell line. TaqMan Universal Master Mix (Applied Biosystems, 
Foster City, California, USA), primers and probes, 96 well optical plates and caps 
were used. Synthesis of first strand cDNA were carried out using Superscript III 
ReverseTranscriptase (Invitrogen) following the manufacturer's protocol using 1 
I-Ig of DNase-treated total RNA. PCR with 1 x final concentration of TaqMan 
Universal Master Mix, 300 nM of each primer and 100 nM of probe in 20 1-11 were 
performed using Applied Biosystems StepOnePlus Real-Time PCR Systems 
(Applied Biosystems). For quantitative RT-PCR of NAT1 (Husain et ai, 2007a) 
and NAT2 (Husain et aI., 2007b), forward primer and reverse primer were used 
with TaqMan probe. 
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NA T1 Genotyping 
DNA was extracted from human fibroblast samples using the "Qiagen 
DNA Purification kit" (Qiagen, Valencia. CA). NAT1 genotype was determined as 
previously described (Doll and Hein, 2002). Briefly, NAT1 amplification was 
carried out in an Applied Biosystems StepOnePlus Real-Time PCR Systems with 
two initial hold steps (50°C for 2 min., followed by 95°C for 10 min.) and 40 
thermocycles of a two-step PCR: 92°C for 15 s, 60° C for 1 min. The fluorescence 
intensity of each sample was measured to monitor amplification of the NAT1 
gene. Primers, probes, and DNA were added to final concentrations of 300 nM, 
100 nM, and 0.5 -2.5 ng/IJI, respectively. 
Measurement of Cytochrome P450 (CYP1 A2) Activity 
Whole cells from geneticin-resistant clones were assayed for CYP1 A2 
activity. Whole cell samples were assayed for 7-ethoxyresorufin O-deethylase 
activity by fluorimetric determination as described by Bendaly et aI., (2007). This 
reaction was conducted in a 96-well plate, containing 1 million cells in 10 IJL of 
PBS with 5 mM glucose and 5 IJM 7-ethoxyresorufin. The reaction was incubated 
at 37°C for 10 minutes. Resorufin formation was measured by fluorescence at 
emission wavelength of 585 nm and excitation wavelength of 530 nm. Cell lines 
exhibiting similar 7-ethoxyresorufin O-deethylase activity comparable to the 
parent cell line (GM4429) were utilized for additional characterization and study. 
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Measurement of N-Acetyltransferase Activitv (in vitro) 
N-acetylation of the NAT1 specific substrate para-aminobenzoic acid 
(PASA), the NAT2 specific substrate sulfamethazine (SMZ), and selected 
arylamines 4- aminobiphenyl (ASP), 2-aminofluorene (AF), benzidine, 2,5-
dimethylaniline (2,5-DMA), 2,6-dimethylaniline (2,6-DMA), 3,4-dimethylaniline 
(3,4-DMA), 3,5-dimethylaniline (3,5-DMA), and 3-ethylaniniline (3-EA) were 
measured using in vitro assays, and acetylated products were separated utilizing 
reverse phase high performance liquid chromatography (HPLC). Reactions were 
prepared with acetyl- coenzyme A (1 mM), substrates (300 IJM), and 50 IJL cell 
lysate and incubated at 3]oC for 10 min. Reactions were stopped by adding 1/10 
volume of 1 M acetic acid and centrifugation at 15,000g for 10 min. Reaction 
products in the resulting supernatant were separated by reverse-phase HPLC. 
HPLC separation for sulphamethazine NAT2 assays was achieved on a C18 
LiChrospher@ 125x4mm column using a gradient 91:9 sodium perchlorate (pH 
2.5) 1 acetonitrile to 71 :29 sodium perchlorate (pH 2.5) 1 acetonitrile over 5 min at 
260 nm. HPLC separation for p-aminobenzoic acid NAT1 reactions was achieved 
using a gradient 96:4 sodium perchlorate (pH 2.5)1 88: 11 acetonitrile at 280nm 
(Hein et. aI., 2006). HPLC separation for 2,6-DMA, 3,5-DMA, and 3-EA was 
achieved using 50:50 acetonitrile and 0.01 M potassium phosphate buffer (pH 5) 
at 1 ml/min at 210 nm (Martin et aI., 1996). 
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N-acetv/ation Activitv (in situ) 
In situ N-acetylation activity was measured in whole cell assays using 
human fibroblasts, grown to confluency in culture medium supplemented with 
substrates PASA, SMZ, ASP, AF, benzidine, 2,5-0MA, 2,6-0MA, 3,4-0MA, 3,5-
OMA, or 3-EA. The cells were incubated at 37°C and media was collected after 
4h, 1/10 volume of 1 M acetic acid was added, and the reaction was centrifuged 
at 13,000g for 10 min. The supernatant was analyzed on the reverse phase 
HPLC column and the N-acetyl substrate was separated and quantitated as 
described above. 
Glutathione S-Transferase (GST) Activitv 
GST activity was measured in human fibroblast lysate using the substrate 
1-chloro-2,4-dinitrobenzene (CONS). A solution of 100 mM potassium 
phosphate buffer pH 6.5 (980 ~I), 200 mM glutathione (1 0 ~I, Sigma Aldrich), and 
100 mM CONS (1 0 ~I, Sigma Aldrich) was added to a 1 ml quartz cuvette and 
mixed. Sample lysate was added to the quartz cuvette containing the substrate 
solution. The absorbance was read at 340 nm on a spectrophotomer every 30 
seconds over a period of 5 minutes after a lag time of 1 minute. The increase in 
absorbance is directly proportional to total GST activity. The GST specific activity 
was calculated usin~ the following equation: 
[flA3401minute (background) - flA3401minute (sample)] 1 [Am (CONS extinction 
coefficient) x mg protein added] = X nmol/min/mg protein 
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Determination of Michaelis Menten Constants towards human NA T1 and NA T2 
Kinetic parameters for ABP, AF, benzidine, 2,5-DMA, 2,6-DMA, 3,4-DMA, 
3,5-DMA, and 3-EA were determined using Iysates of yeast that stably express 
human NAT1 or human NAT2. N-acetylation reactions were conducted as 
described above, but using 0 - 1000 IJM substrate. Data were fit to the Michaelis-
Menten equation and apparent kinetic parameters were determined using 
GraphPad Prism 5 (GraphPad Software, San Diego, CA). 
Measurement of O-acetvltransferase Enzvmatic Activitv 
N-hydroxy-4-aminobiphenyl (N-OH-ABP) O-acetyltransferase activity was 
evaluated using reverse phase HPLC as described by Hein et al. (2006). Briefly, 
reaction mixtures containing 100 IJg total protein, 1 mg/mL deoxyguanosine (dG), 
• 
100 IJM N-OH-ABP, and 1 mM acetyl coenzyme A were incubated at 3JOC for 10 
min. Reactions were stopped with the addition of 100 IJL of water saturated 
ethyl acetate and centrifuged for 10 minutes at 13, 000 g. The organic phase 
was removed, evaporated to dryness, and re-suspended in 100 IJM of 10% 
acetonitrile. HPLC separation was achieved using 80:20 sodium perchlorate (pH 
2.5): acetonitrile over 3 minutes to 50:50 sodium perchlorate (pH 2.5)/acetonitrile. 
dG-C8-ABP adducts were detected by absorbance at 300 nm. 
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DNA Isolation and DNA Adduct Quantitation 
DNA adduct levels were measured as previously described in our 
laboratory (Metry et aI., 2007). DNA was isolated from cells grown in 10 cm 
plates treated with ABP, AF, 2,6-DMA, 3,5-DMA, or 3-EA. ABP was used as a 
positive control in the present study. Cells were harvested after 48 hand 
incubated in 50 IJI of 10% SDS and 20 IJg/ml proteinase K for 45 min at 37 DC. 
DNA was extracted by phenol:chloroform:isoamyl alcohol (25:24:1) and 
preCipitated using cold isopropanol and centrifuged for 1 min. Supernatant was 
removed and the pellet washed with ethanol, dried, and resuspended in buffer 
containing 5 mM Tris HCI, 1 mM CaCI2 , 1 mM MgCb, and 1 mM ZnCI2 . DNA was 
quantified at A26o . 
DNA samples were treated with 10 units DNAase I (US Biological, 
Swampscott, MA) for 1 h at 3]DC and 1 unit nuclease P1 (US Biological) for 6 h, 
followed by overnight treatment with 5 units of alkaline phosphatase (Sigma). 
Two volumes of acetonitrile were added to stop the reaction. Samples were 
filtered using a 5,000 nominal molecular weight limit centrifugal filter device 
(Millipore, Bedford, MA) and were concentrated to 50 IJL. DNA samples were 
reconstituted in 5% acetonitrile to a final volume of 100 IJL. Samples were 
submitted for LC-MS-MS -analysis to the University of Louisville Biomolecular 
Mass Spectrometry Core Facility. Samples used for quantitative analysis were 
spiked with 1 ng deuterated internal standard (dG-C8-ABP-d5) before any 
sample treatment. The samples were reconstituted with 25 IJL 5% ACN in 2.5 
mM NH4HC03 just before analysis and 5 IJL of the sample was analyzed by 
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nanoAcquity Ultra High Performance Liquid Chromatography (UPLC) (Waters, 
Milford, MA) coupled with a L TQ-Orbitrap XL mass spectrometer (Thermo 
Scientific, San Jose, CA). Samples were loaded onto a C18 micro-precolumn 
cartridge (LC Packings, Thermo Scientific, San Jose, CA) and separated with an 
in-house packed C18 capillary column (125 mm x 75 IJ m x 5 IJm). A 15 min 
binary solvent gradient (Solvent A: 0.1 % formic acid and Solvent B: ACN/O.1 % 
formic acid) at 400 nUmin was used. The gradient started from 10% Solvent B, 
increased linearly to 80% Solvent B in 10 min, and then remained at 80% B for 5 
min. The eluates were ionized with a nanospray source and dG-C8-ABP and dG-
C8-ABP-d5 were detected with linear ion trap using the transitions of m/z 435.2 
to m/z 319.2 (dG-C8-ABP) and m/z 440.2 to m/z 324.2 (dG-C8-ABP-d5). 
Amounts of dG-C8-ABP were calculated from peak areas of dG-C8-ABP and dG-
C8-ABP-d5 with a calibration curve from dG-C8-ABP and dG-C8-ABP-d5 
standards. 
Assavs for Mutagenesis at the Hvpoxanthine Phosphoribosv! Transferase 
(HPRT) Locus 
To evaluate mutagenesis at the HPRT locus we employed methods 
previously used in our lab (Metry et aI., 2007). Cells were grown for 12 
doublings, with selective agents in complete HAT medium (30 IJM hypoxanthine, 
0.1 IJM aminopterin, and 30 IJM thymidine). After which cells were grown in the 
prescence of ABP (0 - 500 IJM). Survival was determined by colony forming 
assay and expressed as percent of vehicle control. The remaining cells were re-
plated and sub-cultured. After 7 days of growth, cultures were plated for cloning 
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efficiency in complete media and for mutations in complete medium containing 
40 ~M 6-thioguanine (6-TG) (Sigma). Ten dishes were seeded with 1 x 105 cells 
/100 mm and incubated for 7 days; cloning efficiency dishes were seeded with 
100 cells/ well/ 6-well plate and incubated for 6 days. 
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RESULTS 
Stable Transfections: CYP1A2 ERGO Activity. NAT1 mRNA Expression. and 
Endogenous NA T1 genotype. 
We constructed NER-deficient SV40-transformed human fibroblast cells 
that stably express human NAT2 alleles (NAT2*4, NAT2*SB, or NAT 2*7B) and 
human CYP1 A2, using the Flp-In system (Invitrogen, Carlsbad, CA) as 
described in the methods. No significant differences (p>O.05) in CYP1A2 7-
ethoxyresorufin oxidation catalytic activity were observed between 
GM4429/CYP1 A2 cells and the clones of cells further transfected with NAT2 
alleles (Figure 2.1). No significant (p>O.05) differences in relative NAT1 mRNA 
levels were observed among all cell lines (Figure 2.2). The NAT1 genotype of 
GM4429 cells was NA T1 *4/*4. 
PABA and SMZ N-Acetvlation and NAT2 mRNA Expression Following Stable 
Transfections 
p-Aminobenzoic acid (PABA) is a NAT1-selective substrate. No significant 
difference (p>O.05) in PABA N-acetylation activity was observed among the 
NAT2-transfected GM4429 cells lines (Figure 2.2). Sulfamethazine (SMZ) is a 
NAT2-selective substrate. All NA T2 -transfected cells had significantly higher 
(P<O.01) SMZ N-acetylation activity than the cell lines not transfected with NAT2 
expression constructs (Figure 2.3). SMZ N-acetylation activity in the cell lines 
transfected with the NAT2*4 allele was found to be thirty-five-fold higher than in 
cell lines not transfected with NAT2 expression constructs. Lysates collected 
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from cells transfected with NA T2*58 and NA T2*7B showed significantly lower 
SMZ N-acetylation activity when compared to Iysates of cells transfected with the 
reference allele NAT2*4 (p<0.001). Activity in GM4429 cells not transfected with 
NA T2 were below the level of detection for SMZ N-acetyltransferase «0.15 
nmoles/min/mg). No significant (p>0.05) difference in relative NAT2 mRNA levels 
were observed among all NAT2-transfected cell lines (Figure 2.3.). 
Apparent Michaelis-Menten Kinetics 
As seen in Table 1, recombinant human NAT1 had the highest reaction 
velocity for the N-acetylation of benzidine, AF, and 3,4-DMA. Apparent intrinsic 
activities (V maJKm) of recombinant human NAT1 for the selected substrates were 
in the order of benzidine>3,4-DMA>AF>ABP>3-EA>3,5-DMA>2,5-DMA. 
Recombinant human NAT1 had much lower affinity (higher Km) for the tested 
compounds compared to human NAT2, and catalyzed the N-acetylation of these 
compounds at a much higher rate. 
As seen in Table 2.1, recombinant human NAT2 had the highest velocity 
for the N-acetylation of 3,4-DMA, 3,5-DMA, and ABP. Apparent intrinsic 
activities (VmaJKm) of recombinant human NAT2 were 3,5-DMA>3-EA>AF>ABP> 
AF> benzidine >3,4-DMA > 2,5-DMA. Despite having a high affinity (lower Km) for 
the tested compounds recombinant human NAT2 catalyzed the N-atetylation of 
these compounds at a much slower rate that recombinant human NAT1. 
Recombinant human NAT2 specificity constants for these compounds were in 
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the order of 3,5-0MA>2,5-0MA>3-EA>ASP>AF>3,4-0MA,>benzidine. Neither 
NAT1 nor NAT2 catalyzed the N-acetylation of 2,6-0MA at detectable levels. 
N-Acety/transferase Activity In Human Fibroblast Lines Following Transfections 
Lysates collected from NAT2-transfected and non-transfected cells 
showed no significant difference (p>O.05) in N-acetylation of benzidine, 3,4-0MA, 
and AF (Figure 2.4). Lysates collected from cells transfected with NAT2*4, 
NAT2*58 and NAT2*78 showed significantly higher (p<O.01) N-acetylation of 
3,5-0MA, 2,5-0MA, 3-EA, and ASP when compared to cells not transfected with 
NAT2 (Figure 2.5). Lysates collected from cells transfected with NAT2*58 and 
NAT2*78 showed significantly (p<O.01) lower N-acetylation 3,5-0MA when 
compared to Iysates from cells transfected with the reference allele NAT2*4. 
High and Low CYP1A2 ERGO Activity in Human Fibroblast Cell Lines Following 
NA T2 Transfections 
In order to evaluate the effects of varying (high or low) CYP1 A2 activity on 
N-acetylation of environmental carcinogens, we confirmed the construction of 
NER-deficient SV40-transformed human fibroblast cell lines that stably express 
human NAT2 alleles (NAT2*4, NAT2*58, or NAT2*78) and varying human 
CYP1 A2 activity. Cell lines that are designated "low CYP1 A2" had significantly 
lower (p<O.05) EROO activity than the cell lines designated "high CYP1 A2" 
(Figure 2.6). EROO activity in cell lines expressing alleles NAT2*4, NA T2*58, 
and NA T2*78 having high CYP1 A2 activity were 3, 5, and 8-fold higher than cell 
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lines with the corresponding NA T2 allele and low CYP1 A2 activity, respectively. 
Cell lines transfected only with CYP1 A2 had 12-fold higher EROO activity than 
the null cell line. 
Glutathione S-transferase (GST) Activity 
G8T is a human phase II cytosolic xenobiotic metabolizing enzyme that 
performs detoxification of carcinogens and other environmental pollutants. 
Lysates collected from our transfected cell lines showed no significant difference 
(p > 0.05) in glutathione 8-transferase activity (Figure 2.7). 
In situ PABA and SMZ N-acetvlation Activitv in Human Fibroblast Lines with High 
and Low EROO Activity Following NA T2 Transfections 
As shown in Figure 2.8A, no significant difference (p>0.05) in PA8A N-
acetylation in situ activity was observed among the GM4429 cells lines. All NA T2 
-transfected cells had significantly higher (P<0.01) 8MZ N-acetylation in situ 
activity than the non-transfected cell lines (Figure 2.88). 8MZ N-acetylation in 
situ activity in the cell lines transfected with the NAT2*4 allele was found to be 
significantly higher (p<0.05) than in cells transfected with NA T2*5B and 
NAT2*7B. Activity in GM4429 cells not transfected with NAT2 was non-
detectable. 
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N-acetyltransferase Activity in Human Fibroblast Lines with High and Low 
CYP1A2 Activity 
When measuring benzidine (a NAT1 selective substrate) N-acetylation 
at 20 IJM substrate, no significant differences (p>0.05) were observed when 
comparing cells lines with high or low CYP1 A2 activity and the same NAT2 allele 
(Le., HighCYP1A21 NAT2*4 vs. LowCYP1A2INAT2*4). No significant differences 
(p>0.05) in benzidine N-acetylation activity were observed between 
GM4429/CYP1 A2 cells and cell lines further transfected with NAT2 (Figure 
2.9A). At 200 IJM substrate, when comparing the same allele and high or low 
CYP1A2 enzymatic activity, N-acetylation in HighCYP1A2INAT2*4 cells was 
significantly higher (p<0.05) than that of LowCYP1A2INAT2*4 cell lines (Figure 
2.9b). HighCYP1A2INAT2*78 cells had significantly lower (p<0.05) benzidine N-
acetylation activity than LowCYP1A2INAT2*78 cells. CYP1A2 cells had 
significantly lower (p<0.05) benzidine N-acetylation activity that the null cell line 
(Figure 2.9b). 
At 20 IJM substrate, 3,5-0MA N-acetylation in HighCYP1 A21 NAT2*4 cells 
was significantly higher (p<0.05) than other cell lines. LowCYP1 A2INAT2*4 cells 
had significantly lower (p<0.05) N-acetylation when compared to 
HighCYP1A2INAT2*4 cells. 3,5-0MA N-acetylation with high CYP1A2 activity 
and NA T2 alleles NA T2*78 and NA T2*58 was significantly lower (p<0.05) than 
in cell lines with same allele and lower CYP1 A2 activity. When comparing cells 
transfected with only CYP1 A2, N-acetylation was significantly lower (p<0.05) 
when compared to the null cell line (Figure 2.10a). At 200 IJM, no significant 
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differences (p>0.05) were observed when comparing cell lines that have the 
same NA T2 allele and high or low CYP1 A2 activity. N-acetylation activity for 
CYP1 A2 cell lines was significantly lower (p<0.05) than the null cell line (Figure 
2.10b). 
At an ASP concentration of 20 \.1M, ASP N-acetylation activities in 
GM4429 cells with high CYP1 A2 activity and NAT2 alleles NAT2*4, NAT2*58, 
and NAT2*78 were significantly higher (p<0.05) when compared to cells 
transfected with only CYP1 A2. ASP N-acetylation was significantly lower 
(p>0.05) in cells transfected with NAT2*4 with low CYP1A2 activity when 
compared to HighCYP1 A2I NA T2*4 cells. ASP N-acetylation was significantly 
lower (p<0.05) in NA T2*58/HighCYP1 A2 and CYP1 A2 when compared to 
LowCYP1A2INAT2*58 and null cell lines, respectively (Figure 2.11A). 
At an ASP concentration of 200 \.1M, ASP N-acetylation was significantly 
lower (p<0.05) in GM4429 cells transfected with CYP1 A2 only compared to the 
null cell line and in HighCYP1A2INAT2*58 cells compared to LowCYP1A21 
NAT2*58 cells. ASP N-acetylation was significantly lower (p<0.05) in cells 
transfected with CYP1 A2 only when compared to cell transfected with NAT2. 
N-hvdroxy-A8P O-Acetylation. Cytotoxicity' HPRT Mutants. and dG-C8-A8P 
Adducts 
There were no significant differences (p>0.05) in N-hydroxy-ASP 0-
acetyltransferase activity observed among the non-transfected and NAT2-
transfected cell lines (Figure 2.12). Upon treating cells with ASP, as described in 
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the methods, cytotoxicity, HPRT mutants, and ASP-induced dG-C8-ASP adducts 
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Figure 2.1 CYP1A2 EROO activity in NER-Oeficient SV40-transformed GM4429 
cells. Each bar represents mean ± SEM for 3 experiments determining 7-
ethoxyresorufin-O-deethylase (EROO) activity (pmoles/min/1 x1 06 cells) in NER-
deficient SV40-transformed GM4429 cells stably transfected with human 
CYP1 A2 and human NAT2 alleles. No significant difference in EROO activity was 
observed among transfected cells using one-way ANOVA analysis (p > 0.05) 
EROO activity in non-transfected cells was below the limit of detection «0.05 





















'* Cl 8 
r:: E ~ ~£: 6 ~.- .-
>-.2: E GitsGJ U<C- 4 <C 0 ~ g 




Figure 2.2 Relative NAT1 mRNA and PABA N-acetyltransferase activity in NER-
deficient SV40 transformed GM4429 cells stably transfected with human 
CYP1 A2 and human NAT2 alleles. No significant difference in relative NAT1 
mRNA levels was observed among non-transfected and transfected cells using 
one-way ANOVA (p > 0.05) No significant difference in PABA N-acetylation was 
observed among all GM4429 cells lines using one-way ANOVA (p > 0.05). Each 
bar represents mean ± SEM for 3 experiments. 
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Figure 2.3 Relative NAT2 mRNA and SMZ N-acetyltransferase activity in NER-deficient 
SV40 transformed GM4429 cells stably transfected with human CYP1 A2 and human 
NAT2 alleles. No significant difference in relative NAT2 mRNA levels was observed 
among transfected cells using one-way ANOVA (p > 0.05). All NAT-transfected cells 
had significantly higher SMZ N-acetylation activity than the non-transfected cells. 
Lysates collected from cells transfected with NAT2*S8 and NAT2*78 showed 
significantly lower SMZ N-acetylation activity when compared to cell extracts transfected 
with the reference allele NAT2*4 using one-way ANOVA followed by Bonferroni posttest 
(p<0.001). SMZ N-acetyltransferase activity of non-transfected GM4429 cells was below 
the level of detection «0.15nmoles/min/mg protein). Each bar represents mean ± SEM 
for 3 experiments determining SMZ NAT activity and NAT2 mRNA levels in NER-
deficient SV40-transformed GM4429 cells stably transfected with human CYP1A2 and 





Compound Vmax,app K m, app V max,app/ K m, app Vmax,app K m, app V max,app/ K m, app 
Specificity 
Constant 
(nmoles.min·1• mg'1) (~M) (ml.min·1.mg-1) (nmoles·min-1·mg-1) (~M) (ml.min-1·mg-1) 
PABA 11586 ± 258 984 ± 79.7 11.8 ± 1.9 NO 
Benzidine 8067 ± 488 953 ± 98.1 8.46 ±1.0 7.86 ± 0.28 95.7 ± 48.4 0.85 ± 0.0 9.95 
3,4-0MA 883 ± 48.6 667± 56.4 1.32 ± 0.14 29.8±1.75 66.9 ± 12.1 0.45 ± 0.19 2.93 
AF 8617 ± 4120 3270 ± 195 2.63 ± 0.52 19.8±0.6720 20.5 ± 3.1 0.97 ± 0.1 2.71 
ABP 159 ± 8.7 499.8 ± 56.6 0.32 ± 0.04 20.7 ± 0.10 23.7 ±4.9 0.87 ± 0.2 0.37 
3-EA 169 ± 67.4 1281 ± 79.3 0.13 ± 0.05 19.8±0.67 20.5 ± 3.07 0.97 ± 0.15 0.13 
2,5-0MA 147 ± 56.3 10543 ± 4365 0.01 ± 0.004 7.85 ± 0.28 39.6 ±5.6 0.20 ± 0.03 0.05 
3,5- OMA 469 ± 251 2800 ± 1918 0.02 ± 0.01 23.9 ± 1.39 14.0 ± 3.84 1.70 ± 0.48 0.01 
SMZ NO 53.8 ± 5.9 34.7 ±2.3 1.55 ± 0.2 
2,6-0MA NO NO 
Table 2.1 Michaelis-Menten constants towards human NAT1 and NAT2 recombinantly expressed in yeast. Results 
represent mean ± SEM for three experiments. N-acetylation of 2,6-DMA was not detectable. ND represents activity below 
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Figure 2.4 N-acetylation of NAT1 selective compounds in cell Iysates of 
immortalized human fibroblasts stably transfected with human CYP1A2 and 
human NAT2 alleles. No significant difference in N-acetylation activity was 
observed among cell lines using one-way ANOVA (p > 0.05). Each bar 





Figure 2.5 N-acetylation of NAT2 selective compounds in cell Iysates of 
immortalized human fibroblasts. (A.) 3.5-DMA N-acetylation in non-transfected 
cells and cells transfected with NA T2*58 and NA T2*7B was significantly lower 
than cells expressing the reference allele NA T2*4 denoted by * P < 0.05 ; (B.) 
2,5-DMA, (C.) 3-EA, and (D.) ASP N-acetylation in in non-transfected cells was 
significantly lower than cells expressing the reference allele NA T2*4 denoted by * 
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Figure 2.6 EROO activity in cells from selected immortalized human fibroblast 
clones. Each bar represents mean ± SEM for 3 experiments determining 7-
ethoxyresorufin-O-deethylase (EROO) activity (pmoles/min/1 x1 06 cells). Cell lines 
with low CYP1 A2 activity had significantly lower enzymatic activity when 
compared to cells transfected with the same allele but high CYP1 A2 activity as 
denoted by *P<0.01 using one-way ANOVA analysis followed by Bonferroni 
posttest. EROO activity in non-transfected cells was below the limit of detection 
«0.05 pmoles/min/1 x1 06 cells) as denoted by NO (not detected). 
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Figure 2.7 Glutathione S-Transferase activity in celllysates of SV40-transformed 
human fibroblasts stably transfected with human CYP1A2 and human NAT2 
alleles. No significant difference in GST activity was observed among all GM4429 
cells lines using substrate1-chloro-2,4-dinitrobenzene (CDNB) as determined 








































Figure 2.8 In situ N-acetylation of PABA (A.) and SMZ (B.) in cells from selected 
immortalized human fibroblast clones. No significant difference in PABA N-
acetylation activity was observed among cell lines using one-way ANOVA 
analysis (p > 0.05). Non NAT2-transfected cells and NAT2 -transfected cells 
expressing NA T2*5B and NA T2*7B had significantly lower SMZ N-acetylation 
activity than the reference allele NA T2*4 as denoted by * P<0.01 using one-way 
ANOVA followed by Bonferroni posttest. Each bar represents mean ± SEM for 3 
experiments. 
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Figure 2.9 In situ N-acetylation of benzidine at 20 !-1M (A.) and 200 !-1M (B.) in 
cells from selected immortalized human fibroblast clones. No significqnt 
difference in benzidine N-acetylation activity was observed among cell lines at 20 
!-1M using one-way ANOVA analysis (p > 0.05). Cell lines with CYP1A2-only, 
CYP1A2INAT2*58, and LowCYP1A2INAT2*4 had significantly lower benzidine 
N-acetylation activity at 200 !-1M than the reference allele CYP1A2INAT2*4 as 
denoted by * P<0.01 using one-way ANOVA followed by Bonferroni posttest. 























Figure 2.10 In situ N-acetylation of 3,5-0MA at 20 IJM (A.) and 200 IJM (B.) in 
cells from selected immortalized human fibroblast clones. Cell lines with 
CYP1A2-only, CYP1A2INAT2*S8, and LowCYP1A2INAT2*4 had significantly 
lower 3,5-0MA N-acetylation activity than the reference allele CYP1 A2INAT2*4 
as denoted by * P<0.01 using one-way ANOVA followed by Bonferroni posttest. 






















Figure 2.11 In situ N-acetylation of ABP at 20 IJM (A.) and 200 IJM (B.) in cells 
from selected immortalized human fibroblast clones. Cell lines with CYP1 A2-
.only, CYP1A2INAT2*S8, and LowCYP1A2INAT2*4 had significantly lower ABP 
N-acetylation activity at 20 IJM than the reference allele NAT2*4 as denoted by * 
P<0.01 using one-way ANOVA followed by Bonferroni posttest. Cell lines with 
CYP1A2-only and CYP1A2INAT2*S8 had significantly lower ABP N-acetylation 
activity at 200 IJM than the reference allele CYP1 A2INAT2*4 as denoted by * 
P<0.01 using one-way ANOVA followed by Bonferroni posttest. Each bar 







Figure 2.12 N-hydroxy-ABP O-acetyltransferase activity in immortalized human 
fibroblast that transfected with NAT2 alleles NA T2* 4, NA T2*SB, and NA T2*7B. 
No significant difference in N-hydroxy-ABP O-acetyltransferase activity was 
observed among cell lines using one-way ANOVA analysis (p > 0.05). Each bar 
represents mean ± SEM for 3 experiments. 
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OISCUSSION 
The use of NER-deficient immortalized human fibroblasts to study NAT 
functional genomics and carcinogen metabolism is an innovative addition to the 
previously used Chinese hamster ovary (CHO) cell (Metry et aL, 2007), COS-1 
cell (Zang et aL, 2007), yeast (Fretland et aL, 2001), and E. Coli (Hein et aL, 
1994) models. The use of this cell line provided an opportunity to study human 
CYP1A2, human NAT1, and human NAT2 phenotypic behavior which is 
important to better understand the relationship between risk and carcinogen 
metabolism. Studies have indicated that synergistic effects caused by gene-gene 
interactions increase risk to certain cancers (Cascorbi et aL, 2001 and 
Sanderson et aL, 2007). These findings support the use of cell lines expressing 
human NAT isozymes and human CYP1A2 for functional genomic studies of 
NAT and cancer risk. 
In this study, we determined human NAT1 and NAT2 apparent intrinsic 
activities for the arylamine carcinogens benzidine, ABP, AF, 2,5-0MA, 3,4-OMA, 
3,5-0MA, and 3-EA. We utilized these data to make comparisons of human 
NAT1 and NAT2 substrate affinities for these environmental carcinogens. 
Benzidine, 3,4-OMA, and AF were preferential human NAT1 substrates, while 
3,5-0MA, 2,5-0MA, 3-EA, and ABP were preferential human NAT2 substrates. 
Liu et aL (2007) described similar analyses of the kinetic specificity constants for 
N-acetylation of environmental alkylanilines. In their studies, purified recombinant 
human NAT1 and NAT2 were expressed in E. Coli and used as a model to 
determine substrate selectivity for human NAT1 and NAT2. The Liu et aL (2007) 
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study show similar human NAT1 and NAT2 substrate specificity constants for 
monosubstituted and disubstituted alkylanilines. 
The N-acetylation of 3,5-0MA was significantly lower in cells transfected 
with NA T2*S8 or NA T2*78 allele compared with cells transfected with the 
reference allele NAT2*4. In the case of the most common NAT2 alleles 
(NAT2*4, NAT2*S8, and NAT2*78) our studies suggest that 3,5-0MA has a 
greater toxicological effect for slow NAT2 acetylators because of the significant 
decrease in N-acetylation causing more compound to be available for CYP-
mediated activation. 
NA T1 *10 is a variant haplotype with high allelic frequency that is 
associated with increased cancer risk (Hein et al. 2000). Previous studies 
conducted by Millner et al. (2012) showed that CHO cells transfected with 
NAT1 *10 have higher N- and 0- acetyltransferase activity, mRNA and protein 
expression than cells transfected with the reference allele NA T1 *4. Because 
NAT1 *10 is associated with increased N-acetyltransferase activity, our study 
findings suggest that environmental carcinogens, benzidine, 3,4-0MA, and AF, 
may be less toxic for the population of individuals that possess the NA T1 *10 
allele. This is based on our study findings that indicate that that these substrates 
are preferentially N-acetylated by NAT1 and the ability of NAT1 10 to rapidly 
catalyze the detoxification N-acetylation reaction. 
Our studies using human cell lines that endogenously express NA T1 and 
stably express human NAT2 and human CYP1 A2 confirm results found in the 
previous study. Liu et al. (2007) also describes the use of NMR-based models to 
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analyze NAT binding site interactions of the aforementioned alkylanilines. The 
previous study using purified recombinantly expressed NATs was able to provide 
insight into substrate specificity by determining the contribution of alkylaniline 
substituents to NAT substrate selectivity. These data show that 2-alkyl groups 
decrease N-acetylation catalysis, especially that by NAT1. This trend can be 
seen in our current studies when comparing the NAT1 apparent maximum 
velocity for the alkylanilines. This finding could suggest why 2,6-0MA N-
acetylation was below the limit of detection in both studies. 
Although the previously described study done by Liu et al. (2007) found 
similar results, it did not utilize human cell lines to investigate the role of NAT 
carcinogen metabolism in the presence of CYP1 A2. The present study adds 
considerable valuable to epidemiological studies that study genotype and risk 
alone because our results in human cells suggest that substrate selectivity and 
the interplay of various XMEs play an important role in carcinogen metabolism. 
N-acetylation of benzidine, ASP, and 3,5-0MA was determined in the presence 
of high and low CYP1 A2 activity. We determined that ability of NAT to detoxify 
compounds in the presence of CYP1 A2 is dependent on substrate concentration 
and substrate specificity. This study proposes that toxicological outcomes 
influenced by NAT detoxification are also determined by exposure levels and 
XME competition for available substrate. iV-acetylation in combination with other 
catalysis by other XMEs appears to play an important role carcinogen 
metabolism and risk. 
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In several studies conducted in our laboratory, ASP-induced cytotoxicity, 
mutagenesis, and DNA-adducts were measured in CHO cells stably expressing 
human CYP450 and human NAT (Metry et aI., 2007). Considerable levels of 
these toxicological outcomes were measurable following ASP exposure in CHO 
cells. In the current study, these toxicological outcomes were all below the limit 
of detection in our transfected human cell lines. This result suggests that 
additional human XME present in our cell lines may be acting to detoxify ASP, 
thus inhibiting the ASP-induced toxicological outcomes. 
We determined GST activity in our cell lines by demonstrating the potential 
conjugation of ASP with glutathione. The lack of ASP- induced toxicological 
insult in our studies suggests that GST is involved in the detoxification of ASP. 
GSTs are very abundant cellular components, accounting for up to 10 percent of 
the total cellular protein (Noguti et aI., 2012). This finding is important when 
building a comprehensive understanding of the bioactivation and detoxification of 
environmental carcinogens by XMEs. 
In summary, human NAT1 and NAT2 are both capable of catalyzing the N-
acetylation of benzidine, ASP, AF, 2, 5-DMA, 3, 4-DMA, 3, 5-DMA, and 3-EA. 
These isozymes play an important role in environmental carcinogen metabolism. 
The affinity for these compounds as well as the rate at which these compounds 
are N-acetylated by NAT differ for each isozyme. This study is the first to 
demonstrate the use of human fibroblasts that express human NAT1, human 
NA T2 haplotypes, and human CYP1 A2. Future studies will involve 
characterization of the effects of modulated human GST activity in combination 
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with varying human NAT and human CYP1 A2 activity on toxicological outcomes 
such as mutagenesis and DNA adducts. There are multiple interactions that 
influence the overall biotransformation of environmental carcinogens. We have 
illustrated in this study that the complexities of these competing pathways are 




IDENTIFICATION AND CHARACTERIZATION OF NOVEL HUMAN 
ARYLAMINE N-ACETYL TRANSFERASE SMALL MOLECULE INHIBITORS 
INTRODUCTION 
Many environmental arylamines play an important role in the etiology of 
cancer and require metabolic activation by acetylation. Arylamine N-
acetyltransferases (NAT), phase II xenobiotic metabolizing enzymes, catalyze 
the N-acetylation or O-acetylation of arylamine carcinogens. O-acetylation, which 
is preceded by cytochrome P450 N-hydroxylation, results in nitrenium ions that 
covalently bond with nucleophilic groups on DNA forming adducts. If unrepaired, 
these adducts can lead to mutagenesis and initiate cancer. Humans possess two 
NAT genes, NA T1 and NA T2, which encode similar enzymes that have distinct 
tissue distribution and substrate specificities. NAT1 and NAT2 have been closely 
associated with several types of cancer because of their role in the metabolism of 
arylamine carcinogens. 
NAT1 in particular has been associated with several cancers. Molecular 
epidemiology studies report that NAT1 expression and genetic polymorph isms 
are associated with individual risk to urinary bladder, colorectal, lung, and breast 
cancer. Studies suggest that NAT1 plays an important role in cell growth and 
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survival, as well as in cell proliferation and invasion, which are hallmarks of 
metastatic cancer. 
Collectively, these data implicate NAT1 function in cancer progression and 
malignancy, suggesting that the use of NAT1 as a molecular target may be an 
effective approach for cancer therapy. Several studies have explored the use of 
small molecule inhibitors, providing proof of principle that NAT can be effectively 
inhibited by small molecules (Westwood et aI., 2010), but none has successfully 
developed a novel small molecule inhibitor that is efficacious, potent, and 
nontoxic. 
In order to elucidate ways to reduce or ablate toxicological risk caused by 
arylamine carcinogen metabolism, we explored the identification and use of small 
molecule inhibitors. Studies provide evidence that NAT inhibitors have been 
beneficial in investigating the catalytic mechanism of NATs as these enzymes 
are emerging as molecular targets (Russell et aI., 2009). The purpose of this 
study is to utilize NAT as a molecular target for the development of small 
molecule inhibitors for cancer prevention. We utilized in silico screening of 17 
million compounds to identify those that interact with NAT active sites. The top 
150 compounds were scored and ranked based on their active site association. 
Sixty of these compounds were tested for their ability to inhibit recombinant 
human NAT1. 
I n the present study, we have identified an effective small molecule 
inhibitor that decreases NAT1 activity in yeast and Chinese hamster ovary cells 
that express recombinant human NAT1. In future studies we anticipate that NAT 
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inhibition by our small molecule inhibitor will decrease experimental cancer 
initiation and progression. 
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MATERIALS AND METHODS 
Computational Screening for Small Molecule Inhibitors 
Previously reported high resolution crystal structures of human NAT1 and NAT2 
(Wu et aI., 1997) were used as target structures to identify potential compounds 
with NAT active site association. In collaboration with Dr. John Trent, the human 
NAT protein structures obtained from the Protein Data Bank (PDB) under the 
codes 2PQT (NAT1) and 2PFR (NAT2) were used to complete the screening of 
the ZINC library containing approximately 17 million compounds. The 
computational screening program Surflex-Dock 2.3 was used to perform protein-
ligand docking studies that generated a ranked list of candidates. This docking 
software is capable of ranking the inhibitor candidates by reporting approximate 
binding affinity using a computational parameterized function. Compounds with 
high approximate binding affinity were purchased and investigated for their ability 
to inhibit NAT activity. 
In vitro Screening of N- Acetvltransferase Inhibition 
Initial screening of compounds for their NAT inhibitory properties was 
completed using recombinant human NAT1 or NAT2 stably expressed in yeast 
(Schizosaccharomyces pombe) as previously described (Fretland et aI., 2001). 
Individual reactions were set up using 50 IJL of diluted yeast lysate incubated for 
10 minutes at 3rC in the presence of 300 IJM NAT1 (p-aminobenzoic acid) or 
NAT2 (sulphamethazine) selective substrate, 1 mM acetyl coenzyme A, and 0.1 
mg/mL candidate inhibitor. Reactions were terminated using 10% volume of 1 M 
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acetic acid. Control reactions replaced the inhibitor with the vehicle OMSO. 
Following centrifugation at 15,000 x g for 10 minutes, the supernatant was 
collected and analyzed by high performance liquid chromatography (HPLC, 
Beckman System Gold) as previously described (Chapter II). 
Cell Culture and Preparation of Cell Lvsate 
UV5-Chinese hamster ovary (CHO) cells (CRL-1865) were obtained from 
American Type Culture Collection (ATCC). These cells, previously transfected 
with human NAT1(Miliner et aI., 2012), were cultured at 3rC in 5% CO2 in alpha-
modified minimal essential medium (a-MEM, Lonza, Walkersville, MO) 
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 100 units/mL 
penicillin (Lonza), 100 IJg/mL streptomycin (Lonza), 2 mM L-glutamine (Lonza). 
These cells were allowed to grow to confluency in 6-well cell culture plates 24 h 
before treatment. 
NA T1 In Vitro and In Situ Inhibition Assavs 
In vitro inhibition of NAT1 activity was assayed using 50 IJL of cell lysate 
incubated with 300 IJM PABA, 1 mM acetyl coenzyme A, and various 
concentrations of Compound 10 (0 - 100 IJM) for 10 minutes at 3rC. Reactions 
were terminated by the addition of 10% volume 1 M acetic acid. Following 
centrifugation at 15,000 x g for 10 minutes, the supernatant was collected and 
analyzed by high performance liquid chromatography using a method previously 
described (Chapter II). For in situ studies, 1 x 106 cells were seeded and 
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incubated with 300 IJM PABA and various concentrations (0-1000 IJM) of 
Compound 10 for 24h. The culture medium was collected and N-acetyl-PABA 
was quantified by HPLC. 
In vitro ICso values 
IC50 values of active compounds were determined by nonlinear regression 
using Prism 5 (GraphPad Software Inc., La Jolla, CA). Inhibition kinetics were 
studied in yeast at inhibitor concentrations of 0 - 100 IJM in the presence of 10 
IJM NAT substrates ABP, PABA, or SMZ and 100 IJM acetyl coenzyme A. 
Acetylated products were quantified using HPLC. 
Determination of Compound 10 Kinetics 
CHO cells were treated with a-MEM supplemented with 10 IJM PABA or 
ABP, and various concentrations of Compound 10 (1-500 j.JM). After 2 h 
treatment with various concentrations of Compound 10, NAT1 inhibition was 
determined by collecting 100 IJL of medium and quantifying N - acetyl-PABA 
and N-acetyl- ABP by HPLC as described above. The inhibition type of 
Compound 10 was determined using an Eadie-Hofstee plot prepared by plotting 




Experiments were performed in triplicate. The data are reported as mean 
± SEM. Statistical significance was assessed using one-way analysis of variance 
(ANOVA) for multiple comparisons and Student's t test for single comparisons 
using Prism 5 (GraphPad, La Jolla, CA). 
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RESULTS 
In this study, the protein structures of human arylamine N-
acetyltransferases were used to conduct protein-ligand docking studies. Our 
initial approach in the identification of potential small molecule inhibitors of NATs 
was to perform protein-ligand docking studies using Surflex-Dock 2.3 to generate 
a ranked list of candidates. This program utilizes a docking algorithm that 
positions ligands into the binding site of our enzyme of interest. Surflex-Dock 2.3 
is capable of ranking the inhibitor candidates by reporting approximate binding 
affinity (Kd) using a parameterized function. 
The docking of ligands in the catalytic site of NAT protein was performed 
using Surflex-Dock software. Using the software, 150 compounds were identified 
as potential inhibitors of NAT enzymatic activity. The candidate inhibitors were 
prioritized based on their Surflex-Dock approximated binding affinity. Sixty of the 
top ranking compounds were purchased and experimentally tested for their ability 
to inhibit NAT activity. The percent inhibitions of all compounds were determined 
in vitro in yeast Iysates that express recombinant human NAT1 or NAT2. This 
was determined using the substrates PABA, selective for NAT1, or SMZ, 
selective for NAT2. From these data, we determined NAT selectivity for each 
inhibitor. Compound specificities were determined by dividing the percent NAT1 
inhibition by the percent NAT2 inhibition. Compounds that had a calculated NAT 
selectivity of 1 or above were deemed NAT1 selective. The results obtained from 
the experimental screening are shown in Table 3.1. 
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We selected lead compounds 1,3,5-Triazine-2,4-diamine, 6-[3,5-dimethyl-
1-piperidinyl)methyl]-N-(4-ethoxyphenyl) (2), 9,1 0-dihydro-9, 1 0-dioxo-1 ,2-
anthracenediyl diethyl ester (10), 2-[(3-hydroxyphenyl)methylene] (11), and 4,4'-
methylenebis[N-(1,3-benzodioxol-5-ylmethyl) (16) that exhibited more than 50% 
inhibition at concentrations at or below 1 mg/mL. The protein-ligand structures 
for the lead compounds are depicted in Figure 3.1. Compound 2 inhibited both 
NAT1 and NAT2 with in vitro ICso values of >2 mM and 176 IJM, respectively. 
Compound 11 inhibited NAT1 and NAT2 with in vitro ICso values of 191 and 131 
IJM, respectively. Compound 16 inhibited NAT1 and NAT2 with in vitro ICso 
values of 202 IJM and >2mM, respectively. Compound 10 was the most potent 
inhibitor, in that it inhibited NAT1 and NAT2 with in vitro ICso values of 0.75 and 
82.2 IJM, respectively. The in situ ICso values of our lead compounds were 
determined in UV-5 CHO cells that express recombinant human NAT1. These 
values were 300, 118, and 211 IJM, and >2mM for Compounds 2, 10, 11, and 16 
respectively. These data show that Compound 10 is the most potent inhibitor 
using in vitro and in situ inhibition assays. We note that Compound 10 is 
selective against NAT1 relative to NAT2. Table 3.2 shows the structures of the 
lead compounds and their experimental ICso values. 
The arylamine ASP is a constituent of tobacco smoke, a well-
characterized environmental carcinogen. The N-hydroxylated ASP intermediates 
are able to covalently interact with DNA to form adducts that have the potential to . 
initiate cancer. ASP is biotransformed by both NAT1 and NAT2. We determined 
the ability of Compound 10 to inhibit the in vitro acetylation of ASP by NAT1 and 
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NAT2 in Iysates of yeast that express recombinant human NAT1 or NAT2. The 
IC50 values were determined to be 0.95 and 41.3 IJM for NAT1 and NAT2, 
respectively (Figures 3.2 and 3.3). 
Further studies were completed using the most potent inhibitor, compound 
10, to determine its ability to inhibit N-acetylation of ABP at various 
concentrations in UV5-Chinese hamster ovary (CHO) cells. Compound 10 was 
able to inhibit NAT1 in situ N-acetylation of ABP in UV5-CHO cells that stably 
express recombinant human NAT1. The IC50 value towards the inhibition of N-
acetylation of ABP was 81.6 IJM. These data are shown in addition to the 
inhibition of PABA N-acetylation at various concentrations in Figure 3.2. 
In order to evaluate the kinetic characteristics of compound 10 inhibition, 
UV5-CHO cells were treated with complete media supplemented with substrate 
and various concentrations of inhibitor. These kinetic data were used to 
construct Eadie-Hofstee and Lineweaver-Burke plots (Figure 3.3). These studies 
demonstrated noncompetitive binding, which may be indicative of tight binding or 
irreversible inhibition. Tight binding is speculated due to the nature in which the 
inhibitors were identified, active site association. 
Two available structural analogs 1-(9,1 0-dihydro-8-hydroxy-9, 1 0-dioxo-1-
anthracenyl)4-ethyl ester (analog 1) and 9,1 0-dihydro-9, 1 0-dioxo-1 ,8-
anthracenediyl diethyl ester (analog 2) of Compound 10 were tested for their 
ability to inhibit NAT1. The in situ IC50 values of these analogs were determined 
to be 384 and 147 IJM, respectively. The structures and IC50 values of analogs 1 
and 2 are shown in Table 3.3. 
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To characterize the identified inhibitors we utilized the simulation software 
ADMET Predictor (Simulations Plus) to predict QSAR descriptors of our lead 
compounds. The physiochemical properties of the lead compounds and analogs 
are presented in Table 3.4. All compounds, except Compound 16, satisfied 
Lipinski's rule-of-five. This rule is based on the World Drug Index Database and 
is used to evaluate the compounds potential to become a drug (Lipinski et aI., 
2000). This evaluation is based on properties of -90% of drugs on the market 
that have a (1) a molecular weight less than 500, (2) a partition coefficient that 
is less than 5, (3) less than 5 hydrogen bond donors (sum of O-H and N-H), and 
(3) less than 10 hydrogen-bond acceptor (sum of Nand 0 atoms). Compound 16 
did not satisfy Lipinski's rule-of-five due to a molecular weight greater than 500. 
We also utilized the ADMET predictor software to predict the cytochrome P450 
intrinsic clearance constants of the lead compounds and Compound 10 structural 
analogs. This program predicts the intrinsic clearance for the major CYPs that 
are responsible for -90% of CYP-mediated reactions. These isoforms include 
CYP1 A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4. These data are shown 
in Table 3.5. Our lead compound, 10, is predicted to have no violations of 
ADMET properties; therefore we have identified an inhibitor of human arylamine 
N-acetyltransferase that can be used for further biological testing to better 
understand the role that NAT1 plays in cancer progressi6n. 
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% Inhibition of % Inhibition 
Compound Targeted Priority PABA NAT of NAT1 
number Activity SMZ NAT Specificity Isozyme (NAT1) Activity (NAT1/NAT2) 
(NAT2) 
1 NAT2 6 0 4 0 
2 NAT2 9 7 49 0.14 
4 NAT1 14 0 3 0 
5 NAT1 19 30 0 
6 NAT2 7 0 7 0 
7 NAT2 11 25 0 
8 NAT1 3 0 0 
9 NAT1 20 14 7 2.00 
10 NAT1 23 100 100 1.00 
11 NAT1 40 95 88 1.08 
12 NAT1 67 8 23 0.35 
13 NAT1 3 0 
14 NAT1 7 0 
15 NAT2 24 5 9 0.56 
16 NAT2 23 75 5 15.00 
17 NAT1 27 0 0 
18 NAT2 25 0 0 
19 NAT1 47 16 2 8.00 
20 NAT2 28 16 2 8.00 
21 NAT1 50 2 9 0.22 
23 NAT2 26 5 21 0.24 
24 NAT2 27 15 22 0.68 
25 NAT2 30 2 37 0.05 
26 NAT1 26 31 0 
27 NAT2 46 0 0 
28 NAT2 57 0 26 0 
30 NAT1 49 0 7 0 
31 NAT2 52 27 14 1.93 
32 NAT1 54 43 30 1.43 
33 NAT2 53 7 0 
34 NAT2 33 14 10 1.40 
35 NAT2 22 0 2 0 
36 NAT2 41 0 0 
37 NAT2 32 17 4 4.25 
38 NAT2 60 21 13 1.62 
39 NAT2 67 5 0 
40 NAT2 58 3 0 
41 NAT2 56 0 2 0 
42 NAT2 49 14 0 
43 NAT2 55 0 27 0 
44 NAT2 68 13 10 1.30 
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% Inhibition % Inhibition 
Targeted Priority of of NAT1 Compound PABA NAT SMZ NAT Specificity Isozyme Number Activity Activity (NAT1/NAT2) 
(NAT1) (NAT2) 
45 NAT2 51 20 0 
46 NAT2 38 21 15 1.40 
47 NAT2 44 5 14 0.36 
48 NAT1 33 17 54 0.31 
49 NAT1 22 11 60 0.18 
50 NAn 24 33 29 1.14 
51 NAn 68 0 23 0 
52 NAT1 14 11 20 0.55 
53 NAT1 63 24 12 2.00 
54 NAT1 53 48 13 3.69 
Table 3.1 In vitro screening against human NAT1 and NAT2 recombinantly 
expressed in yeast. Priority numbers were assigned based on computational 
screening approximated binding affinities. 
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Figure 3.1 Protein-ligand poses for lead compounds 2, 10, 11, and 16 (left to 
right) using Surflex-Dock 2.3. 
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NAT2 
In vitro In vitro ICsol In situ 
Compound Structure NAT11Cso NAT21Cso NAT1 NAn 
(IJM) (IJM) ICso ICso(IJM) 
tl 
~ \ 
2 ~0'Q NY {~ 0- >2mM 176 ± 24.3 0.08 300±20.4 ~ A~" N N 
10 
\~-d-P 





191 ± 33.9 131 ± 15.7 0.69 211±30.8 
N 
16 >2mM 9.90 >2mM 
Table 3.2 Structures of lead compounds and the experimental IGso values. The 
IGso values of the most efficacious inhibitors (compounds 2, 10, 11 and 16) were 
determined in vitro against human NAT1 (PABA) and NAT2 (SMZ) recombinantly 
expressed in yeast. The in situ IGso values were determined in UV5-GHO cells 
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Figure 3.2 In vitro NAT1 and NAT2 activity was determined using 100 IJM 
acetyl coenzyme A and 10 IJM 4-aminobiphenyl (ABP), p-aminobenzoic acid 
(PABA), or sulfamethazine (SMZ) with varying concentrations of Compound 10 
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Figure 3.3 Kinetic characteristics of Compound 10 inhibition. Seeded CHO cells 
were treated with complete a-MEM supplemented with 10 IJM PABA substrate 
(S), and various concentrations of Compound 10 (1 - 500 !-1M). After 2 h 
treatment with various concentrations of Compound 10, NAT1 inhibition was 
determined by collecting 100 !-IL of media and quantifying N - acetyl-PABA by 
HPLC. Eadie-Hofstee (A.) and Lineweaver-Burke(B.) plots showing 
noncompetitive inhibition and are indicative of tight-binding. Velocity (V) is in 
units of nmole/min. 
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In vitro In vitro In situ 
Entry No. Compound NAT1 NAT2 NAT1 ICso ICso ICso 
(IJM) (IJM) (IJM) 
( 
Analog 1 0 0 I' 171±4.7 >2mM 384±12.2 o 0 C¢) /C /C 
0 
0) 
'/' Analog 2 % 94~.8 >2mM 147±9.4 I 0 
/C, 0 
o I '" o~o/' 
-0- oJ 
Table 3.3 Compound 10 Analog 1 and Analog 2 structures and experimental IC50 
values determined in vitro in yeast lysate against human NAT1 (PABA) and 
NAT2 (8MZ), and in situ in UV5-CHO cells that stably express recombinant 
NAT1. 
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Compound 2 10 11 16 Analog 1 Analog 2 
MlogP 3.29 0.91 0.84 2.05 1.69 0.91 
S+logD 3.85 2.74 1.64 3.84 2.95 3.06 
S+Vd (Ukg) 3.42 1.03 1.05 0.68 0.58 0.93 
Diffusion 
Coefficient 0.7 0.65 1.25 0.6 0.8 0.65 
Lipinski Rule 
of Five 0 0 0 1(MW) 0 0 
Table 3.4 ADMET Predictor Calculated QSAR descriptors of lead compounds 
and Compound 10 analogs. MlogP is the Moriguch model of octanol-water 
partition coefficient. S+logP is the Simulations Plus model octanol-water 
distribution coefficient. S+Vd is the Simulations Plus model pharmacokinetic 
volume of distribution. The molecular diffusion coefficient is predicted for water 
with units of cm2/sx1 05. A 0 indicates that the compound does not dissatisfy any 
of the Lipinski rules. The number 1 indicates that Compound 11 dissatisfies 1 
rule for molecular weight (MW). 
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Compound 2 10 11 16 Analog 1 Analog 2 
CYP1A2 35.6 0.18 0.074 0.12 0.35 0.23 
CYP2C19 0.64 0.002 0.002 0.04 0.09 0.04 
CYP2C9 0.02 0.04 0.05 69.2 3.5 0.86 
CYP2D6 3.0 0.01 0.01 0.02 0.01 0.01 
CYP3A4 1.52 1.49 0.17 1.77 0.045 1.62 
Table 3.5 ADMET Predictor predicted CYP intrinsic clearance constants 
(ml/min/kg) of lead compounds and Compound 10 analogs. 
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DISCUSSION 
Here, we report the identification and characterization of novel small 
molecule inhibitors of the molecular target NAT1. The most important conclusion 
of this study is that structure-based computational screening was used to identify 
effective inhibitors of NAT1. The data provided in this study reveal that 
compound 10 is an effective and potent inhibitor of human NAT1. Compound 10 
appears to be the most suitable compound for further inhibitor development and 
for studies that determine the effects of NAT1 inhibition on cancer progression. 
We wish to note that this study shows proof-of-concept that virtual screening 
methods are a viable approach to identifying novel inhibitors of enzymes that 
playa role in carcinogen metabolism. 
Although this was a relatively small-scale study with only 60 compounds 
tested, 4 new lead compounds were discovered. We can utilize these 
compounds to gain a better understanding of the role that human arylamine 
NAT1 plays in cancer progression. Compound 10 was less effective in whole cell 
assays, possibly due to lower bioavailability due to poor absorption. 
In this study, we identified and tested structural analogs of compound 10 
that were not as effective in inhibiting NAT1 activity. We speculate that the 
structural analogs lack the inhibition ability of 10 because the positioning of 
binding moieties are not optimally positioned to interact with the three key amino 
acids in the active site loop. Further investigation is needed to validate these 
speculations. 
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In conclusion, the present study further suggest that NAT1 can be used as 
a molecular target and it identifies a novel small molecule inhibitor that may 
prove to be most promising as an anticancer therapeutic. While known NAT1 
inhibitors, such as tamoxifen, have provided insight into the role of NAT1 in 
carcinogen metabolism, small molecule inhibitors have established a new era in 
the use of NAT1 as a molecular target for cancer drug development. 
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CHAPTER IV 
INHIBITION OF HUMAN ARYLAMINE N-ACETYL TRANSFERASE I 
DECREASES EXPERIMENTAL CANCER INITIATION AND PROGRESSION 
INTRODUCTION 
In order to elucidate ways to reduce or to ablate toxicological risk caused 
by arylamine carcinogen metabolism, we explored the identification and use of a 
small molecule inhibitor. Studies provide evidence that NAT inhibitors have been 
useful in investigating the catalytic mechanism of NATs as these enzymes are 
emerging as molecular targets (Russell et aI., 2009). Other studies explore NAT 
inhibitors as a means to alter biotransformation by NAT, consequently providing 
potential differences in toxicological consequences (Dairou et aI., 2009). 
Our study introduces the use of novel and effective inhibitors of NAT1 to 
reduce experimental cancer initiation and progression. Recent studies provide 
evidence that NAT1 knock-down affects cell growth and morphology, suggesting 
that NAT1 may function beyond a Phase" drug metabolizing enzyme, further 
raising the potential of NAT1 as a therapeutic molecular target (Tiang et aI., 
2011). Collectively, these data implicate NAT1 function in cancer progression 
and malignancy suggesting that the use of NAT1 as a molecular target may be 
an effective approach for cancer therapy. In Chapter III, we identified a small 
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molecule inhibitor that decreases NAT1 activity in yeast and Chinese hamster 
ovary cells that recombinantly express human NAT1. 
Studies have shown that NAT1 is highly expressed in breast tumors as 
compared to normal tissue, being especially elevated in invasive ductal and 
lobular breast carcinomas (Russell et aI., 2009). Other studies suggest that 
NAT1 plays an important role in cell growth and survival, as well as in cell 
proliferation and cell invasion, which are hallmarks of metastatic cancer (Tiang et 
aI., 2010). In this chapter, we use the small molecule inhibitor, Compound 10, to 
decrease NAT1 activity in human breast cancer cell lines, MDA-MB-231 (post 
epithelial to mesenchymal transition) and MCF-7 (luminal), in order to study the 
effects of NAT1 inhibition on carcinogen metabolism and cancer progression in 
two different breast adenocarcinoma cell lines. 
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MATERIALS AND METHODS 
Cell Culture and Preparation of Cell Lvsates 
MDA-MB-231 (HTB-26) and MCF-7 (HTB-22) human breast 
adenocarcinoma cells were obtained from American Type Culture Collection 
(ATCC). Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM , 
Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum (Hyclone, 
Logan, UT), 100 units/mL penicillin (Lonza), and 100 I-Ig/mL streptomycin 
(Lonza). Non-tumorigenic human breast epithelial cells (MCF-10A) were a gift 
from Mrs. Sheila Thomas (University of Louisville, James Graham Brown Cancer 
Center). Cells were cultured in Mammary Epithelium Basal Medium (MEBM, 
Lonza, Walkersville, MD) supplemented with bovine pituitary extract (2 mL I 500 
mL MEBM, Lonza), epidermal growth factor (0.5 mL I 500 mL MEBM, Lonza), 
insulin (0.5 mL I 500 mL MEBM, Lonza), transferrin (0.5 mL I 500 mL MEBM, 
Lonza), hydrocortisone (0.5 mL I 500 mL MEBM, Lonza), epinephrine (0.5 mL, 
500 mL MEMB Lonza), and gentamicin (0.5 mL I 500 mL MEBM, Lonza). Cells 
were maintained at 37°C in 5% CO2. MDA-MB-231 and MCF-7 cells were 
trypsinized with 0.25% Trypsin-EDTA (Gibco). MCF-10A cells were trypsinized 
with 1 X TrypLE™ Express (Gibco). To prepare cell Iysates, cells were washed 
with cold PBS and resuspended in homogenization buffer (20 mM NaP04 at pH 
7.4, 1 mM EDTA , 2 I-Ig/mL aprotinin, 0.1 mM phenylmethanesulfonyl fluoride 
(PMSF), 2 mM pepstatin A, 1 mM dithiothreitol, and 0.2% Triton X-100) on ice. 
Homogenates were centrifuged at 15,000 x g for 10 min at 4 cC. Total protein 
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concentrations in supernatants were determined by the Bradford method 
(Bradford, 1976). 
Drug Treatment 
Compound 10 was dissolved in DMSO for each experiment. Stock solutions 
were stored at -20°C and used for further dilution in culture medium to obtain 
desired concentrations. The final solvent concentration was 0.5% v/v of DMSO. 
Control cultures of cells for each experiment were grown in culture medium with 
DMSO used as control. 
Inhibition of NA T1 In Situ 
Cells were grown to confluence and treated with media supplemented with 
10 IJM ABP or PABA with varying concentrations of Compound 10 (0 - 1000 IJM) 
for 4h at 37°C. The culture media were collected and 1/10 volume of 1 M acetic 
acid was added. The mixture was centrifuged at 13 000 g for 10 min. The 
supernatant was analyzed by reverse phase HPLC and N-acetyl-PABA or ABP 
products were quantitated as described in Chapter II. 
Cell Viabilitv and Proliferation Assav 
The effect of Compound 10 on cell viability and cell proliferation was 
assayed using the AlamarBlue (Invitrogen, Eugene, OR) fluorescence assay. 
MDA-MB-231 and MCF-10A cells were seeded in 96-well plates and incubated 
for 24 h. The cells were then treated with varying concentrations of Compound 
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10 in their respective culture medium. AlamarBlue, resazurin, is a nontoxic non-
fluorescent indicator dye that is converted to highly red fluorescent resorufin via 
reduction in living cells. AlamarBlue was added 1 h prior to the desired time 
point in an amount equal to 1/10 of the culture volume, and the plates were 
further incubated at 37°C. The amount of AlamarBlue reduction was measured 
using a fluorometric plate reader (excitation wavelength of 570 nm and emission 
of 580 nm). Data are reported as the mean ± SEM fluorescence intensity versus 
Compound 10 concentration for 4 separate experiments. 
Measurement of O-Acetyltransferase Activity 
N-hydroxy-4-aminobiphenyl (N-OH-ABP) O-acetyltransferase activity was 
evaluated in MDA-MB-231 cell lysate using reverse phase HPlC as described by 
Hein et aI., (2006). Reaction mixtures containing 100 IJg total protein, 1 mg/ml 
deoxyguanosine (dG), 100 IJM N-OH-ABP, 1 mM acetyl coenzyme A, and 
Compound 10 (0-100 IJM) were incubated at 3]oC for 10 min. Reactions were 
stopped with the addition of 100 IJl of water saturated ethyl acetate and 
centrifuged for 10 minutes at 13, 000 g. The organic phase was removed, 
evaporated to dryness, and re-suspended in 100 IJM of 10% acetonitrile. HPlC 
separation was achieved using a gradient of 80:20 sodium perchlorate (pH 2.5): 
acetonitrile over 3 minutes to 50:50 sodium perchlorate (pH 2.5)/acetonitrile and 
dG-C8-ABP adducts were detected at a wavelength of 300 nm. 
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DNA Isolation and dG-G8-ABP Quantitation 
DNA was isolated as previously described by Bendaly et. al. 2009. Cells 
were incubated in alpha-MEM media containing 12.5, 40, and 200 I-IM ABP and 
various concentrations of Compound 10 (0-250 I-IM). After cells reached 
approximately 90% confluency, cells were harvested. The cells were centrifuged 
for 5 min at 13, OOOg, and the cell pellet was resuspended in homogenization 
buffer, 0.1 volume of 10% SDS, and 0.1 volume of Proteinase K and incubated 
overnight at 37° C. The DNA was extracted using phenol/choloroform:isomyl 
alcohol and precipitated with isopropanol. The pellet was dried and resuspended 
in 500 I-IL of DNA adduct buffer (5 mM Tris pH 7.4, 1 mM CaCI2, 1 mM ZnCI2, and 
10 mM MgCI2). The DNA was quantitated by spectrophotometry, A26o. 
Evaluation of Gel/Invasion 
To determine the effects of Compound 10 on invasive potential of MDA-MD-231 
cells, we utilized the CytoSelectTM 24-well cell invasion assay, colorimetric 
format (Cell Biolabs Inc., San Diego, CA). The assay was completed according to 
the manufacturer's protocol. Cells (300,000) were seeded and allowed to invade 
towards culture media containing 10% FBS for 24 h in the presence of various 
concentrations (0, 31.25, 62.5, and 125 I-IM) of Compound 10. Cells on the 
bottom of the polycarbonate membrane were stained, extracted, and the 
absorbance was quantified at 560 nm. Cell invasion was plotted as the 
percentage of controls (DMSO). 
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Flow Cvtometric Analvsis of Cell Cvcle 
For cell cycle analysis MDA-MB-231 cells were treated with Compound 10 (0 -
250 IJM) in culture media for 144h. Cells were harvested by trypsinization and 
fixed in 70% ethanol at 4°C overnight. Fixed cells were collected by 
centrifugation and washed with cold PBS. Cells were then stained with 0.1 
mg/mL propidium iodide in 0.6% Triton-X in the presence of RNase A (100U/mL 
final, Sigma) for 1 h in the dark at room temperature. Cell cycle analysis was 
performed on a FACSCalibur according to manufacturer's protocol (BD 
Biosciences). A minimum of 20,000 cells were analyzed per sample. Data were 
collected and analyzed using FlowJo Software (Ashland, OR). 
Real-time-PCR for Rr£ Profiler PCR Arrav 
MCF-7 cells were cultured in medium treated with Compound 10 (0 and 125 IJM) 
for 24 h. Cells were harvested by trypsinization and total RNA was isolated using 
the RNeasy kit (Qiagen) followed by removal of contaminating DNA by treatment 
with TurboDNase Free (Ambion, Austin, TX). Synthesis of first strand cDNA 
was performed using Genomic DNA Elimination Mixture provided by the Human 
Breast Cancer RT2 Profiler PCR Human Breast Cancer Array (SA Biosciences) 
according to manufacturer's protocol. This -real-time PCR array profiles the 
expression of 84 key genes commonly involved in biological processes during 
breast carcinogenesis and in breast cancer cell lines. The PCR components (2x 
RT2 SYBER Green Mastermix, cDNA synthesis reaction, and RNase-free water) 
were dispensed into the RT2 Profiler PCR Array and applied to the Applied 
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Biosystems StepOnePlus Real-Time PCR System (Applied Biosystems). 
Differences in mRNA levels were determined in comparison to the control 
(DMSO). Fold-change values greater than one indicated a positive- or an up-
regulation, and the fold-regulation is equal to the fold-change. Fold-change 
values less than one indicated a negative or down-regulation, and the fold-
regulation is the negative inverse of the fold-change. 
Mitotic Indices 
MDA-MB-231 cells were treated with Compound 10 (0, 62.5, and 250 I-lM) for 24, 
48, 72, and 144h. Cells were harvested and prepared for mitotic index as 
previously described by States et. al 2002. Briefly, cells were resuspended in 
serum-free 0.4% KCI for 10 min at 37°C. Fixative solution (methanol:acetic acid, 
3:1,v/v) as added at 2% total volume. Cells were fixed at room temperature for 
20 min. Cells were then dropped onto slides and allowed to air dry. Slides were 
then stained with Wright-Giema, allowed to dry, and examined under a 
microscope. 
Western Blotting 
The effect of Compound 10 on NAT1, Cyclin B 1, and Cyclin 01 protein 
expression in UV5-CHO or MDA-MB-231 cells was evaluated by western blot. 
Cells were cultured at 37°C in 5% CO2 in alpha-modified minimal essential 
medium (a-MEM, Lonza, Walkersville, MD) supplemented with 10% fetal bovine 
serum (Hyclone, Logan, UT), 100 U/mL penicillin (Lonza), 100 I-lg/mL 
streptomycin (Lonza), and 2 mM L-glutamine (Lonza) and treated with 
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Compound 10 (0, 62.5, and 250 IJM) for 96 h. After which, cells were harvested 
by trysinization and Iysates were prepared as previously described above. 
Approximately 20 IJg of cell lysate were mixed with 1:1 5% ~-mercaptoethanol in 
Laemmli buffer (Bio-Rad), boiled for 5 min, and resolved by 12% SOS-PAGE gel. 
The proteins were transferred by semi-dry electroblotting to polyvinylidene 
fluoride (PVOF) membrane. The membranes were probed with the primary 
mouse monoclonal IgG G5 (NAT1, 1 :2000, Santa Cruz Biotechnology), SC245 
(cyclin B1, 1 :2000, Santa Cruz Biotechnology), or Cyclin 01 (cyclin 01, 1 :2000, 
Santa Cruz Biotechnology), and with horse radish peroxidase (HRP) -
conjugated secondary goat anti-mouse IgM antibody (Santa Cruz 
Biotechnology). West Pico Chemiluminescent substrate (Pierce) was used for 
signal detection and densitometric analysis was performed using Quantity One 
Software (Bio-rad laboratories, Hercules, CA) . 
Statistical Analysis 
Statistical differences were assessed using one-way analysis of variance 
(ANOVA) for multiple comparisons or an unpaired Student's t test for single 
comparisons using Prism 5 (GraphPad, La Jolla, CA). 
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RESULTS 
Compound 10 decreases endogenous NA T1 activity and ABP-induced DNA 
adducts 
MDA-MB-231 and MCF-7 human breast adenocarcinoma cells were 
incubated with several concentrations of compound 10 in the presence of NAT1 
substrates PABA and ABP. As illustrated in Figure 4.1, compound 10 inhibited 
endogenous ABP and PABA N-acetylation activity in both human breast cancer 
cell lines in a dose dependent manner. In MDA-MB-231 cells compound 10 at 
the highest concentration, 250 IJM, completely inhibited ABP N-acetylation. 
Similar effects were seen in both cell lines. 
We postulated that a decrease in N-acetylation through inhibition of NAT1 
would result in a decrease in toxicological outcomes associated with NAT1 
metabolism. In order to test this hypothesis we evaluated the effect of Compound 
10 on the N-hydroxy-ABP O-acetylation and ABP-induced dG-C8-ABP adduct 
formation. We utilized MDA-MB-231 cells to determine if Compound 10 inhibition 
would cause a decrease in endogenous O-acetylation activity. As illustrated in 
Figure 4.2, Compound 10 decreased N-hydroxy-ABP O-acetyltransferase activity 
in a dose-dependent manner. Coupled with cytochrome P450 hydroxylation, 0-
acetylation of N-hydroxylated amines contributes toward the activation of 
carcinogenic amines such as ABP. These N-acetoxy compounds, such as N-
acetoxy-ABP, will form arylnitrenium ions resulting in DNA adducts. If these 
adducts are not repaired through cellular DNA repair mechanisms, mutations will 
occur that initiate cancer progression. To further explore the ability of NAT1 
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inhibition to decrease adduct formation we treated both UV5-CHO and MDA-MS-
231 cells with ASP in the presence of Compound 10. Compound 10 decreased 
the formation of ASP-induced dG-C8-ASP adducts in UV5- CHO cells stably 
expressing CYP1A1 and NAT1*4 (Figure 4.3a). Compound 10 was not as 
effective in decreasing ASP-induced adducts in the MDA-MS-231 cells (Figure 
4.3b). We speculate that this is because, unlike UV5-CHO cells, MDA-MS-231 
cells are able to repair DNA adducts. Together these data confirm that 
Compound 10 is able to inhibit endogenous NAT1 N-acetylation and 0-
acetylation activity, consequently reducing ASP activation and ASP-induced dG-
C8-ASP DNA adduct formation in UV5-CHO and human adenocarcinoma breast 
cells. 
Compound 10 inhibits cell proliferation in a highlv metastatic human breast 
cancer cell line 
To further elucidate the role of NAT1 in cell proliferation, we examined the 
effect of NAT1 inhibition by Compound 10 on cell proliferation. Initially, we tested 
the effect of Compound 10 on cell viability in order to address any concern that a 
decrease in NAT1 activity was caused by Compound 10 toxicity. Cell viability 
was measured by the AlamarSlue fluorescence assay. This nontoxic dye detects 
functional oxidative phosphorylation in order to determine the number of viable 
adherent and floating cells which is indicated by fluorescence intensity. 
We evaluated Compound 10 toxicity in MDA-MS-231 cultured in medium 
treated with various concentrations of Compound 10 for 4, 24, 48, 72, and 144 h. 
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Fluorescence intensity was measured at time points 4 - 48 h to determine effects 
of Compound 10 on cell viability. These time points correspond to the periods at 
which NAT1 activity inhibition experiments were conducted (4 h) and are within 
doubling times for these cells. Compound 10 did not decrease cell viability of 
MDA-MB-231 (Figure 4.4a) or MCF-7 (Figure 4.4b) cells at these time points. 
Fluorescence intensity increases at these time pOints indicate that Compound 10 
did not affect cell viability. These cell viability data were also utilized to 
determine if Compound 10 inhibition affects cell proliferation. Figure 4.4 also 
illustrates that at time points 72 and 144h, there is a dose-dependent decrease in 
cell proliferation. This was determined by the decrease in fluorescence intensity 
which is indicative of a decrease in cell number. These data demonstrate that 
while Compound 10 is not toxic to MDA-MB-231 cells, at longer time points 
(above 72 h) cell proliferation is disrupted. 
One major concern when developing a therapeutic inhibitor is the effect 
the compound will have on non-tumorigenic cells at later time pOints. Therefore, 
we also tested the ability of Compound 10 to decrease cell viability and 
proliferation in a non-tumorigenic cell line, MCF-10A. As seen in Figure 4.4, a 
similar pattern was observed in the non-tumorigenic cells (MCF-10A) as in the 
tumorigenic cells (MDA-MB-231). Cell viability of MCF-1 OA cells was not affected 
as indicated by fluorescence intensity at early time pOints. However, as seen in 
MDA-MB-231 cells, a decrease in cell proliferation was observed in the non-
tumorigenic cell line. A comparison between the tumorigenic and non-
tumorigenic cell lines was established to determine selectivity of Compound 10 
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for tumorigenic cells. This was achieved by calculating the corresponding ICso for 
cell proliferation at 72 h in MCF-10A and MDA-MB-231 which resulted to be 113 
and 32 IJM respectively. We also calculated the in situ therapeutic index (TI) = 
ICso non-tumorigenic cells/ ICso tumorigenic cells. The TI for Compound 10 is 
3.4, which shows moderately low toxicity towards non-tumorigenic human breast 
epithelial cells. These data show that inhibition of NAT1 activity by Compound 
10 disrupts cell proliferation in tumorigenic and non-tumorigenic human breast 
cell lines. These data support previous findings that suggest that NAT1 plays an 
important role in cell proliferation, and consequently is a molecular target for 
cancer therapy. 
Compound 10 treatment suppresses cell invasion 
Cell invasion is considered one of the hallmarks of progression in 
metastatic cancers. Cell migration is an important facilitator of cell invasion 
because once cells gain the ability to migrate to distal organs and tissues, cell 
invasion can ensue. Our studies have shown that Compound 10 can suppress 
the migration of MDA-MB-231 (Figure 4.5) and MCF-7 (Figure 4.6) cells in a 
dose-dependent manner. Cells treated with a non-cytotoxic dose of Compound 
10 for 24 h demonstrated a decrease in cell migration. These results suggest 
that Compound 10 can decrease cell invasion of metastatic breast cancer cells. 
Although we have shown that Compound 10 can decrease the invasion potential 
of these human breast cancer cells, the exact mechanism is unknown. 
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Effect of Compound 10 on NA T1 Levels 
In order to investigate the possibility of the decrease in NAT1 activity in 
cultured cells being a result of a decrease in NAT1 protein, we evaluated the 
expression of NAT1 protein after Compound 10 treatment. UV5-CHO cells were 
incubated at 37°C for 3 d in the presence of 0, 62.5, and 250 IJM Compound 10. 
These data (Figure 4.8A) show that Compound 10 does not affect NAT1 protein 
expression in cultured cells. 
Effects of Compound 10 on cell cycle progression 
We evaluated the effects of Compound 10 on cell cycle progression by 
measuring mitotic indices of human breast cancer cells treated for 24, 72, and 
144 h. The mitotic index of treated cells increased in a dose- and time-
dependent manner (Figure 7). We used western blot analysis to evaluate the 
protein expression of cell cycle cyclins 81 and D1. Cyclin 81 expression 
significantly (p<0.05) increased with increasing dose, while Cyclin D1 protein 
expression remained the same (Figure 4.8). 
Compound 10 causes differential expression of genes involved in human breast 
carcinogenesis 
We investigated the potential mechanism of action of Compound 10 by 
evaluating gene expression changes using PCR array. There were 11 genes 
87 
that were up-regulated upon Compound 10 treatment and 13 genes that were 
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Figure 4.1 Inhibition of in situ NAT1 capacity in human breast adenocarcinoma 
MDA-MB-231 (a) and MCF-7 (b) cells that express endogenous NAT1. These 
cells were treated with media supplemented with 10 !-1M ABP or PABA with 
varying concentrations of Compound 10 (0 - 250 !-1M). Reaction products were 
collected and analyzed using high-performance liquid chromatography (HPLC) to 
determine the amount of acetylated product. Each point represents mean ± SEM 
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Figure 4.2. Compound 10 inhibition of N-OH-ABP O-acetyltransferase activity in 
human breast adenocarcinoma cells (MDA-MB-231) that express endogenous 
NAT1. Assays containing 50 ~g protein, 100 ~M N-OH-ABP, 1 mM acetyl 
coenzyme A, 1 mg/mL deoxyguanosine, and Compound 10 (0 -1 00 ~M) were 
incubated for 10 min. at 3JOC. Reactions were stopped with the addition of 100 
~L of water saturated ethyl acetate and centrifuged at 13,000xg for 10 min. The 
organic phase was removed, evaporated to dryness, dissolved in 1 00 ~L of 10% 
















"C ~ 50 co~ 
c.. 
~ 



















Log [Compound 10] (J.1M) 
= O+-------~--------~------~ Y 0 
~ 1 2 3 
"C Log [Compound 1 0] (J.LM) 
3 
Figure 4.3 Percent ASP-induced dG-C8-ASP adduct formation in (A.) UV5-CHO 
cells stably expressing CYP1A1 and NAT1*4 and (B.) MDA-MB-231 cells that 
express endogenous NA T1 *4. ASP-induced dG-C8-ASP adducts/108 
nucleosides were quantitated by mass spectrometry after cells were treated with 
Compound 10 for 24h. Adduct formation was plotted as the percentage of 
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Figure 4.4 Determination of Compound 10 effect on cell viability and cell 
proliferation using AlamarBlue® fluorescence assay in (A.) tumorigenic MDA-
MB-231 and (B.) non-tumorigenic MCF-10A cells. Cells were plated and 
treated with Compound 10 at various concentrations (0- 250 !-1M) for up to 144h, 
AlamarBlue® was added in an amount equal to 10% (v/v) volume directly to the 
cells in culture media 1 h prior to the desired time pOint. The fluorescence was 
read using a fluorescence excitation wavelength of .570 nm and emission of 580 
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Figure 4.5 A. Inhibition of cell invasion by Compound 10 in MDA-MB-231 cells. 
300,000 cells were seeded and allowed to invade towards culture media 
containing 10% FBS for 24 h in the presence of various concentrations (0, 31.25, 
62.5, and 125 IlM) of Compound 10. Cells on the bottom of the polycarbonate 
membrane were stained, extracted, and the absorbance was quantified at 560 
nm. Cell invasion was plotted as the percentage of untreated cells (control). 
Each point represents the mean ± SEM for 3 experiments. Figures 4.58 - C. 
Representative photographs of invasive cells from cell invasion assay at 
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Figure 4.6 Inhibition of cell invasion by Compound 10 in MCF-7 cells. Cells were 
seeded and allowed to invade towards culture media containing 10% FBS for 24 
h in the presence of various concentrations (0, 31.25, 62.5, and 125 IJM) of 
Compound 10. Cells on the bottom of the polycarbonate membrane were 
stained, extracted, and the absorbance was quantified at 560 nm. Cell invasion 
was plotted as the percentage of untreated cells (control). Each point represents 













Figure 4.7 Mitotic index of MDA-MB-231 treated with compound 10. Cells were 
treated for 24, 72, and 144h with 0, 62.5, and 250 ~M compound 10 and 
resuspended in serum-free media with 0.4% KCI, Fixed in methanol:acetic acid, 
3:1,v/v, dropped onto slides and allowed to air. Slides were stained with Wright-
Giema, allowed to dry, and examine under a microscope. A total of 200 cells 
were counted per slide. Mitotic index was significantly (p< 0.05) lower at 0 ~M 
than at 72 and 144 h timepoints when compared to 62.5 and 250 ~M at the 
same time pOints. Each bar represents mean ± SEM for 3 slides. 
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A. Yeast NAT1 
positive control 0 IJM 62.5 IJM 250 IJM 
a-Tubulin 
NAT1 
B. OIJM 62.5 IJM 250 IJM 
Cyclin 81 
a-Tubulin 
c. 62.5 IJM 250 IJM 
Cyclin 01 
a -Tubulin 
Figure 4.8 We~tern blot analysis of NAT1, Cyclin 81, and Cyclin 01 protein 
expression following Compound 10 treatment. UV5-CHO (NAT1 protein 
expression) or MOA-MO-231 (Cyclin 81 and 01) cells were treated with 0, 62.5, 
and 250 IJM compound 10 for 4 days. Cellular lysate proteins were resolved by 
SOS-PAGE, transferred to PVOF membranes, and probed for NAT1 , Cyclin 81 , 
or Cyclin 01. 
96 
A. 
Gene Name Fold Up-regulation 
Mitogen-activated protein kinase 3 2.0654 
Snail homolog 2 (Drosophilia) 2.1834 
Cyclin A1 2.3178 
Retinoblastoma 1 2.4152 
Rass association domain family 2.4531 
member 1 
Mutl homolog 1 , colon cancer, 2.4887 
nonpolYPosis type 2 
Hypermethylated in cancer 1 3.1823 
ATP- binding cassette, sub-family B 3.566 
Keratin 5 5.2782 
Matrix metallopeptidase 2 6.1539 
Cyclin E1 7.9511 
B. 
Gene Name Fold Down-regulation 
Glutathione S -transferase -1.5425 
BaculovirallAP repeat containing 5 -1.5335 
GLI family zinc finger 1 -1.5089 
X-box binding protein 1 -1.416 
Cyclin D2 -1.3628 
Slit homolog (Drosophila) -1.3425 
ADAM metallopeptidase domain 23 -1.3361 
Breast cancer 2, early onset -1.2611 
Solute carrier family 39(zinc 
-1.2402 transporter), member 
Interleukin 6 (interferon, beta 2) -1.1377 
Cyclin-dependent kinase inhibitor 2A -1.1158 
Cystastin ElM -1.0643 
Nuclear receptor subfamily 3, group 
-1.0622 C, member 1 
Table 4.1 Gene expression fold changes in MCF-7 cells treated with Compound 10 (0 
and 125 I-IM) for 24h. Total RNA was harvested and reverse-transcribed for subsequent 
real-time PCR analysis assaying the expression of a series of 84 genes linked to human 
breast cancer progression. Genes showing significant increase (A.) and decrease (8.) in 
fold change compared to untreated cells (the control) are listed. Genes that did not show 
differential expression after treatment are not shown. 
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DISCUSSION 
Studies have implicated arylamine NAT1 in tumor and cancer progression 
(Tiang et aL, 2010). Its expression has been associated with the incidence of 
many cancers such as breast, lung, and bladder cancers. Accordingly, NAT1 is 
a proposed molecular target for cancer therapy. In the current study, we report 
that our lead compound ethyl[1-(3-ethoxycarbonylpropanoyloxy)-10-dioxo-2-
anthryl-butanedioate (Compound 10) is a novel small molecule inhibitor of NAT1 
that suppresses experimental cancer initiation and progression. Compound 10 
displayed an in vitro and in situ IC50 that demonstrates greater potency when 
compared to previously reported NAT inhibitors, such as tamoxifen (IC5o = 57 
J.JM) (Kawamura et aL, 2008). A decrease in G-acetylated product with NAT 
inhibition suggests that this inhibitor decreases carcinogen activation in human 
breast cancer cells. These data are important in that they provide further 
evidence that NAT is becoming increasingly important as a novel therapeutic 
target. 
We recognize that in order to strengthen this study, NAT1 binding assays 
using differential scanning calorimetry are important. Precise experimental 
methods to determine ligand-binding affinity are needed to enhance drug 
discovery (de Azevedo et aL, 2008). However, isolated NAT1 is very unstable 
(Husain et aL, 2007) making these experiments very difficult to perform. A prior 
study showed that Compound 10 as a chemotherapeutic agent to reduce the 
growth of transplanted tumors in mice (Gal et aL, 1952). Our study is the first to 
provide insight on the mechanism of action for this compound. 
98 
We have utilized PCR arrays to show that NAT1 activity may be related to 
cell signaling pathways that are important in human breast cancers. These data 
will allow us to explore these cell signaling pathways in order to better 
understand the mechanistic role of NAT1 in cancer progression. Our studies 
suggest that NAT1 plays an important role in cell cycle progression. These data 
show an increase of mitotic indices and mitosis-related cyclin 81 upon 
Compound 10 treatment. These results provide insight to the role that NAT1 
plays in cancer progression. Until recently, the role of NAT1 in cancer 
progression was attributed only to its role in arylamine carcinogen metabolism. 
Here not only do we support recent findings that implicate NAT1 in cell growth 
and proliferation, but we suggest a potential role that NAT1 may play a role in 
regulating cell cycle progression. Future studies include investigation into the 
use of chemopreventive natural products in combination with Compound 10 to 
enhance the chemopreventive effects of our lead inhibitor. We are also 
exploring the use of differential scanning calorimetry to confirm ligand-protein 
binding. 
Cancer is a major public health concern in the United States. The 
American Journal for Clinicians estimates that in 2012 there will be an estimated 
1.6 million new cases of cancer. Although, the rate of cancer in both men and 
women has declined, progress needs to be made in reducing incidence and 
mortality rates. Therefore further progress in new discoveries in cancer 
prevention, early detection, and treatment is important. In conclusion, these data 
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suggest that NAT can be used as a molecular target for the treatment of cancers 
related to NAT1 expression and the activation of environmental carcinogens. 
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
This dissertation project used computational and experimental methods to 
provide an in depth understanding of the role that human arylamine N-
acetyltransferase plays in carcinogen metabolism and cancer progression. 
These studies provide clarity and future direction for functional genomic and 
epidemiological studies that seek to explain relationships between carcinogen 
exposure, metabolism, and cancer susceptibility. In this study, we have made 
progress towards understanding the mechanistic role that NAT1 plays in cell 
proliferation and cell cycle, and therefore cancer progression. 
Functional genomic studies in human fibroblasts 
In Chapter 1, we described the successful construction and use of NER-
deficient immortalized human fibroblast cell lines in order to better understand 
the role of human NAT1 and NAT2 in carcinogen metabolism and substrate 
selectivity. Our model allowed us to provide inSight into functional genomic 
studies that seek to clarify relationships between human NAT1, human NAT2, 
and human CYP1A2. The data obtained in this study show that arylamine NAT 
compound selectivity influences disposition and detoxification of well-
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characterized and putative arylamine carcinogens that are persistent in the 
environment. Furthermore, this study suggests that known genetic 
polymorph isms in enzymes that metabolize environmental carcinogens may be 
more biologically relevant to substrates that show selectivity for such enzymes. 
For example, our studies show that known NAT2 genetic polymorph isms should 
be most biologically relevant for the putative carcinogen 3,5-DMA. These findings 
can be used to predict overall inter-individual risk of carcinogenesis based on 
haplotype and exposure. 
The phase I XMEs CYP450s can lead to the activation of procarcinogens 
to electrophilic intermediates that cause DNA damage and toxicity. Studies 
suggest that CYP levels not only affect tumor initiation, but signal transduction 
pathways, which alter cell cycle, tumor promotion, and tumor progression (Nebert 
et. aI., 2006). In this study, we sought to determine the effects of varying CYP-
mediated activation on NAT detoxification. Although our model mimics the 
classical interaction of environmental carcinogens and phase I and phase II 
XMEs, our data were inconclusive suggesting that our model is too Simplistic and 
more work needs to be completed to understand the complex interplay between 
phase I and phase II enzymes that work in concert. 
Our laboratory has reported in several studies substantial levels of 
cytotoxicity, mutagenesis, and DNA adduct formation upon treatment with ASP in 
Chinese hamster ovary cells stably expressing human NAT1. Similar findings 
were not seen in our human fibroblast lines which led us to the investigation of 
total GST. We found that our human fibroblast lines express GST activity, which 
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may have contributed to the detoxification of the well-characterized carcinogen 
ASP. Due to the lack of ASP-induced toxicological outcomes in the human cells 
used in the present study, we have concluded that epidemiology studies may 
benefit from studying the effects of genetic differences in multiple XMEs that 
contribute to carcinogen metabolism and cancer susceptibly. These combinatory 
functional genomic studies may provide insight to the effects of complex 
phenotypes, a trait caused by two or more genes and environmental factors, on 
individual risk to environmental carcinogen-induced cancer. 
Small molecule inhibition of NAT1 
Computational modeling studies were used to identify effective small molecule 
inhibitors of human NAT1. Upon confirming effective small molecules of NAT, 
we evaluated the effects of therapeutic inhibition of NAT1 on carcinogen 
metabolism and cancer progression. The data in this dissertation show that 
NAT1 inhibition decreases ASP O-acetylation and ASP-induced DNA adducts in 
CHO cells stably transfected with human NAT1. Our studies also support 
previous findings that suggest that NAT1 plays an important role in cell 
proliferation and cell invasion. The most effective inhibitor, Compound 10, in this 
study decreased cell proliferation and cell invasion in human breast cancer cell 
lines. These findings suggest that pharmacological inhibitors of NAT1 could lay 
the foundation for cancer therapeutic applications that use NAT1 as a molecular 
target. Future protein-ligand binding studies are required to confirm NAT1 
protein binding. In addition to confirming NAT1 binding, it is important to 
determine off-target effects caused by NAT1 inhibition using our lead compound. 
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We could utilize computational systems that explore structural and metabolomic 
data to identify and to compare ligand binding sites on protein structures. This 
future study will allow the prediction of off-target binding sites across the human 
proteome. This type of computational study, as described by Chang et. al. 
(2010) uses a novel integration of structural and systems biology to screen the 
human proteome to identify off-target drug-binding sites. We can utilize this list 
of potential off target binding sites to focus on putative metabolic off-targets. Our 
laboratory could then consider the off-targets that impact cancer progression to 
confirm that the inhibition of cancer progression is a NAT1 inhibition response. 
NAT1 inhibition and cell cycle regulation 
We utilized Compound 10 to investigate the mechanistic role that NAT1 
plays in cancer progression. We performed pathway -focused RT2 Profiler PCR 
arrays to evaluate the gene expression of 84 genes that regulate signal 
transduction and other biological processes during human breast cancer 
progression. In this study, inhibition of NAT1 in human breast cancer cells (MCF-
7) was associated with differential expression of genes that playa role in human 
breast cancer including genes that are important in cell cycle, adhesion, 
apoptosis, and angiogenesis. Because our data also showed an increase in 
mitotic index after treating human breast cancer cells with our NAT1 inhibitor, we 
were especially interested in the differential expression of the profiled cyclins. 
Although cyclin B, a M phase cyclin, was not included in the PCR array, we 
confirmed by Western Blotting that after Compound 10 treatment there was a 
significant increase in cyclin B expression. These findings suggest that 
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independent of carcinogen metabolism, NAT1 plays an important role in 
carcinogenesis through cell cycle regulation, moreover mitotic progression. 
Folate is a water-soluble B vitamin that is essential for DNA synthesis, 
DNA methylation, and cell division. Folate is especially important during periods 
of rapid cell division making rapidly dividing cells more susceptible to folate 
metabolism disruption (Minchin et aI., 2012). P-aminobenzyolglutamate (PABG), 
a folate catabolite, is the only known endogenous NAT1 substrate (Minchin et aI., 
2012). PABG is acetylated by NAT1 and the acetylated product is excreted from 
the cell. This process influences the regulation of folate metabolism. PABG can 
compete with folic acid for folate-binding protein causing it to act as an antagonist 
to some folate dependent enzymes (Minchin et aI., 1995). Studies have shown 
that in transgenic mice, high NAT1 activity is associated with low folate levels. 
Therefore, NAT1 is suspected to be a modulator of folate catabolism (Cao et aI., 
2010). 
We postulate that inhibiting NAT1 decreases the N-acetylation of PABG, 
which increases PABG cellular levels resulting in feedback inhibition of the folate 
catabolism pathway. As reported in the literature, a disruption in folate 
metabolism results in impaired cell division, reduced cell growth, decreased DNA 
repair, and changes in epigenetic modifications (Krupenko et. aI., 2002). 
Although our hypothesis needs to be further investigated, our results suggest that 
NAT1 inhibition plays an important role in cell proliferation and mitosis by 
indirectly modulating cellular folate levels. 
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